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ABSTRACT
INTRODUCTION
Open, observational studies of intradetrusor injections of Botulinum toxin for 
detrusor overactivity have reported beneficial effects. This thesis reports the 
testing of the efficacy and safety of Botulinum toxin B (BTX-B) for treatment of 
the overactive bladder in a randomised, double-blind, placebo controlled 
cross-over trial.
METHOD
20 patients, aged 18-80 years, with detrusor overactivity, and incompletely 
responsive to oral antimuscarinic agents, participated. They were injected with 
either placebo (20 mis normal saline) or botulinum toxin B (5000 IU diluted up 
to 20 mis) into the detrusor in a day case setting. After six weeks, the 
treatments were crossed over without washout. The primary outcome was the 
paired difference in change in the average voided volumes. Paired differences 
urinary frequency, incontinence episodes and in the quality of life (QOL), 
measured by the King’s Health Questionnaire (KHQ), were the secondary 
outcome measures.
4On the occasion of each injection two biopsies were taken from the detrusor. 
These were processed and scrutinised for evidence of inflammatory 
responses to the injection.
RESULTS
The Wilcoxon Signed Ranks Test was used to test the paired difference in 
change between treatment phases. Statistically significant paired differences 
in the change in average voided volume, urinary frequency and episodes of 
incontinence between active treatment and placebo (Av Void Vol: 95% Cl diff 
16, 122; Z = -2.5; p=0.012 / Weekly Freq: 95% Cl -21, -1; Z = -2.1, p=0.033 / 
Weekly incont: 95% Cl -26, -7; Z=-3.3; p=0.001) along with significant paired 
differences in five domains of the KHQ were observed.
CONCLUSIONS
This double-blind, placebo-controlled, cross-over study provides evidence of 
efficacy of Botulinum Toxin B in the treatment of the overactive bladder. 
Autonomic side effects were observed in four of the patients. The short 
duration of action will presumably limit the use to patients who have 
experienced tachyphylaxis with (Botulinum toxin A) BTX-A.
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Chapter 1 INTRODUCTION
1.1 HISTORY
Botulinum toxin has long been recognised as an extremely potent, naturally 
occurring poison 1. It is a neurotoxin produced by the bacterium Clostridium 
botulinum. Christian Andreas Justinus Kemer, a German physician and poet, 
was the first to publish an account of botulism as a food-borne disease in 
spoiled pork sausages2. This substance, Kemer suggested, might be used in 
the future as a therapeutic agent in patients with involuntary movements as a 
result of neurological disease. However, it would be 160 years before the first 
therapeutic use of BTX was reported in humans. The actual bacterium was 
isolated by Ermengem after an outbreak of sausage-related poisoning in 1894 
in the small village of Ellezelles, in Holland 3. In 1944, military bacteriologists 
and physicians on both sides of the Atlantic were assigned to study and purify 
BTX, leading to the production of a crystalline form of type A BTX (BTX-A), 
one of the more common forms in human outbreaks 4. In 1968, Schantz and 
Scott collaborated in developing a therapeutic formulation of BTX-A and used 
it successfully in correcting strabismus in experimental monkeys 5. Of the 
seven neurotoxic serotypes (A-G), type A and type B have been introduced 
into clinical practice 6
17
1.2 STRUCTURE
Although the seven neurotoxins are antigenically distinct, they possess similar 
molecular weights and have a common subunit structure 7. The complete 
amino acid sequences for various toxins are becoming known 8'17.
The botulinum toxin molecule is synthesised as a single chain and then 
cleaved and spliced to form the dichain molecule with a disulfide bridge. In the 
single chain form the molecules have a mass of 150 kD and relatively little 
potency as neuromuscular blocking agents.
Neurotoxic activation requires a two step modification in the tertiary structure 
of the protein. In the first step, as already stated, the parent chain is cleaved 
and spliced. The result is a heavy chain (approx. 100kDa) tethered by a 
disulfide bond to a light chain (approx 50 kDa) that is associated with one 
atom of zinc 18.
For most forms of the toxin this step is accomplished by the bacterium itself 
before it is released.
The light chain amino acids (1-448) act as a zinc endopeptidase, with 
proteolytic activity concentrated at the N-terminal end.
The heavy chain (amino acids 449-1280) provides cholinergic specificity and 
promotes light chain translocation at the end of the endosomal membrane. 19
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Figure 1.1
Structure of Botulinum toxin showing the light chain and the 
heavy chain linked by a disulfide bond
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1.3 FORMULATION AND ADMINISTRATION
Botulinum toxin (Btx) type B is available in Europe as Neurobloc™ and is 
supplied in vials containing 2,500 IU(0.5ml), 5,000 IU (1.0ml) or 10,000 
IU(2.0ml). Units refer to biological activity (LD 50 in the Swiss Webster mouse 
potency assay), not a specific weight of the protein. It should be noted that 
one IU of protein A is not equivalent to protein B.
Botulinum toxin B is always in solution and does not require lyophilization and 
so it retains almost 100% of its specific activity 20,21.
Botulinum Toxin type A is stored unconstituted in the freezer (<= -5° C), 
however type B can be stored refrigerated (2-8° C) for upto 36 months and at 
room temperature for at least 9 months without losing stability or potency. The 
relative stabilities of the two toxins may reflect, in part, the slightly acidic 
formulation of type B at pH 5.6.
Use of this pH confers extended stability for type B product in solution. At 
more neutral or slightly basic pH values, botulinum toxin complexes 
completely dissociate, markedly affecting stability and potency.
Studies have shown that type B diluted upto six fold with either preserved or 
non preserved saline, remain stable and retain potency for at least 24hrs at 
room temperature22.
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1.4. MECHANISM OF ACTION 
1.4.1 PHYSIOLOGY OF SMOOTH MUSCLE CONTRACTION
Since the effects of BTX are secondary to inhibition of acetylcholine release, it 
is important to discuss this neurotransmitter and the various receptors it acts 
on, in further detail.
Acetylcholine (Ach) was one of the first neurotransmitters to be discovered, 
(originally called ‘vagusschtuff’ because it was found to be the substance 
released by stimulation of the vagus nerve that altered heart muscle 
contractions).
1.4.2 SYNTHESIS OF ACETYLCHOLINE
Synthesis of acetylcholine is facilitated by the enzyme, choline 
acetyltransferase (CAT). This enzyme combines choline with acetate derived 
from acetyl coenzyme A (CoA). Choline is taken up into cholinergic nerves by 
a high affinity transport process (sodium-choline cotransport) that is indirectly 
coupled to the energy stored by the Na/K pump ATPase. This transporter 
process is inhibited by hemicholinium-3 (HC-3). HC-3 has no immediate effect 
on neurotransmission, but can cause cholinergic nerve fibres eventually to run 
out of transmitter. In the presence of HC-3, the more rapidly cholinergic fibres 
are stimulated, the more rapidly they run out of ACh.23
21
Chi
O '  ~-------
( lioline = o
h sC ''' '^ s ' ' CoA
A ce ty l C oA
C oA S H
O  CH S
A cety lcho line
Figure 1.2 
Chemical structure of acetyl choline
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Structure of a neuromuscular junction containing 
acetyl choline vesicles
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1.4.3 STORAGE AND RELEASE OF ACETYLCHOLINE
The uptake of ACh into synaptic vesicles in the cholinergic nerve fibres is 
inhibited by the drug vesamicol. In the presence of vesamicol, cholinergic 
fibers rapidly become depleted in stored ACh. Neurotransmission fails 
although other metabolic functions of the fibres are still intact. Release of 
acetylcholine, like synaptic release at other junctions, is based on quantal 
release of vesicles containing preformed neurotransmitter molecules. 
Vesicular release depends on depolarization of the nerve terminal and the 
influx of calcium ions. In ways not yet understood in detail, the influx of 
calcium promotes simultaneous exocytosis of many vesicles. At the motor 
end-plate of the neuromuscular junction this results in a massive release of 
ACh (hundreds of vesicles and thousands of ACh molecules per vesicle) and 
substantial depolarization of end-plate potential that normally results in 
contraction of the muscle cell. The effect of background quantal release of 
ACh-containing vesicles can be observed as miniature end plate potentials 
(mepps). The release of ACh at various cholinergic junctions can be blocked 
by certain toxins, most notably those produced by Clostridium species. 
Botulinum toxin , from Clostridium botulinum binds to cholinergic nerve 
terminals and is internalized. Once internalized it acts on the vesicle release 
process and prevents exocytosis. All junctional release of ACh is inhibited by
24
such toxins. In patients poisoned by Clostridium botulinum the immediate 
clinical problem is flaccid paralysis and respiratory failure.23
1.4.4 ACTIONS OF ACETYLCHOLINE AND RECEPTORS
Acetylcholine (ACh) has diverse actions on a number of cell types mediated 
by two major classes of receptors. Nicotinic receptors are ligand-gated ion 
channels. Muscarinic receptors are part of the transmembrane, G protein 
coupled receptor family.
There are two major subtypes of nicotinic receptors; those found in the 
neuromuscular junction of skeletal muscle (nicotinic muscle, Nm) and those 
found in autonomic ganglia and other parts of the nervous system (nicotinic 
neuronal, Nn). When ACh or other agonists occupy the receptor site on the 
external surface of the cell membrane there is a conformational change in the 
ion channel and an increase in conductance to the ion(s) for which that 
channel is selective. Thus, when Nm receptors are activated, there is an influx 
of cations through the ion channel and depolarization of the motor end plate.
In short, nicotinic receptors directly transduce the ACh external messenger 
into an action on the cell. 23
25
N2-Ligand-gated ion channel: at Neuromuscular Junction.
5-subunits
4-TM Ds each
O utside
II ll ll ll ll
Inside
Ach opens Na+ 
causing depolarization 
and subsequent action 
potential at NMJ.
N2-nicotinic NMJ 
binds to:
decamethonium > 
hexamethonium
Figure 1.4 
N2 ligated- gated ion channel at the 
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Transduction of the ACh message is more complex in the muscarinic family of 
receptors which are more complex than the nicotinic family. There are at least 
five muscarinic receptor subtypes expressed in humans. For most purposes it 
is sufficient to concentrate on M1, M2 and M3 receptors. M1 receptors are 
located in autonomic ganglia and the central nervous system. M2 receptors 
are located mainly in the supraventricular parts of the heart. M3 receptors are 
located in smooth muscles and glands, and on endothelial cells in the 
vasculature.
M1 and M3 receptors are coupled to the enzyme phospholipase C (PLC) 
through a G protein. When the receptor is activated the enzyme increases 
splitting of phosphatidylinositol polyphosphates of the cell membrane into 
(mainly) inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 
contains many charged phosphate groups and is water soluble. It is thus 
released into the interior of the cell and acts on IP3 receptors on the surface 
of the endoplasmic (or sarcoplasmic) reticulum.23
IP3 receptors increase the release of Ca++ from the ER and increased 
cytosolic Ca++ is thus part of the intracellular message from ACh at the 
surface membrane. In the example illustrated here, an M3 receptor on a 
smooth muscle cell promotes smooth muscle contraction by promoting 
increased cytosolic free Ca++ ion.
27
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Another link in the transduction from ACh at the cell surface is DAG. This is 
lipid soluble and remains in the cell membrane. With increased intracellular 
Ca++, DAG activates a kinase, protein kinase C (PKC). Which regulates a 
number of other enzyme activities.
Recapitulating, M1 and M3 receptors generally mediate excitatory responses 
in effector cells. Thus, M1 receptors promote depolarization of postganglionic 
autonomic nerves, and M3 receptors mediate contraction of all smooth 
muscles (an apparent exception to be noted below) and increased secretion 
in glands. It is useful to remember that excess ACh levels in the body as 
occurs with acetylcholinesterase inhibitor poisoning are associated with Gl 
cramping, salivation, lacrimation, urination, etc. 23
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1.5 DIFFERENT TARGET SITES FOR DIFFERENT BOTULINUM TOXINS
The botulinum toxins are synthesised as single chain polypeptides with a 
molecular mass of approximately 150kDa. In this form, the toxin molecules 
have little potency as neuromuscular blocking agents.
Neurotoxic activation requires a two stage modification in the tertiary structure 
of the protein 24. In the first step, the parent chain is cleaved and spliced. The 
result is a heavy chain (approx 100 kDa) tethered by a disulfide bond to a light 
chain (approx 50 kDa) that is associated with 1 atom of zinc 25. For most 
forms of botulinum toxin, including type A, this cleavage is accomplished by 
the bacterium itself before the toxin is released and enters the axon terminal. 
The second activating step, disulfide reduction, occurs only after 
internalisation by the target cell.
There are three processes involved in toxin mediated paralysis;
(1) Internalisation, (2) Disulfide reduction and translocation, and (3) Inhibition 
of neurotransmitter release.
The toxin must enter the nerve ending to exert its effect 26. Binding of toxin to 
both peripheral and central nerves is selective and saturable. Pharmacologic 
and morphologic data suggest that the internalisation is via a receptor
30
mediated endocytotic / lysosomal vesicle pathway 27 30 The process is 
independent of Ca2+concentration, is partially dependent on nerve 
stimulation, and requires energy 31. In experimental systems, internalisation is 
hastened in an acid medium and slowed by cooling.
In vitro studies with synaptosomal preparations suggest heterogeneity of 
receptor sites, with both high and low affinity ligands and some specificity for 
toxin type 32,33. The C terminal half of the heavy chain determines cholinergic- 
nerve specificity and is responsible for binding, while the light chain is the 
intracellular toxic moiety. If the disulfide bond that links the two chains is 
broken before the toxin is internalised by the cell, the light chain cannot enter 
and there is complete loss of toxicity. After internalisation, the disulfide bond is 
cleaved by an unknown mechanism, and the end terminal half of the heavy 
chain promotes penetration and translocation of the light chain across the 
endosomal membrane. This ultimately disrupts the secretory pathway for 
acetylcholine 34. Botulinum toxin specifically targets acetylcholine release, 
rather than synthesis or storage 34’ 35. Nerve endings which are poisoned with 
the toxin can still be induced to release the normal quanta of acetylcholine, 
although non physiologic techniques must be used.
Like tetanus toxin, Botulinum toxin is a zinc endopeptidase. The proteolytic 
activity is located in the N-terminal 50 kDa light chain. The binding of the zinc 
ion to the light chain is reversible and involves coordination with histidines, as 
is characteristic of zinc endopeptidases 36. Acetylcholine release is inhibited
31
when the endopeptidase cleaves one or more neuronal proteins of the vesicle 
transport pathway.
The ATP dependent translocation of an intact vesicle from the cytosol to the 
plasma membrane requires a suite of specific proteins. Cleavage of any of 
these proteins interferes with the proper binding and fusion of a vesicle to the 
plasma membrane, and therefore impedes exocytosis mediated 
neurotransmitter release.
The intracellular traffic patterns responsible for this translocation have 
become clearer during the past several years. Vesicle docking on the inner 
membrane surface involves the formation of a complex including cytoplasmic 
proteins (gamma- SNAP, alpha-SNAP, NSF, SNAP-25), vesicle proteins 
(VAMP/Synaptobrevin), and proteins on the target membrane (Syntaxin). The 
clostridial neurotoxins are now known to target some of these proteins. 37
Schiavo and Dasgupta, showed the intracellular substrate for both Botulinum 
toxin-B and tetanus toxin to be the vesicle protein, (VAMP/Synaptobrevin-2)
38. The botulinum toxin-B light chain activity is specific for 
VAMP/Synaptobrevin-2 (VAMP/SYB-2), as shown in the rat where this 
isoform is targeted while VAMP/Syanptobrevin-1 is spared. This proteolysis 
inhibits the release of neurotransmitter. Botulinum toxin-D and F also cleave 
VAMP/Synaptobrevin-2, but at a different site than BTX-B 39. BTX-A and BTX-
32
E cleave another translocation protein, SNAP 25, and BTX-C acts by cleaving 
syntaxin 40(figure 1.6)
33
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Figure 1.6 Targets for proteolysis by Botulinum toxins in the 
SNARE complex. Different botulinum toxins mediate paralysis 
by cleaving different SNARE proteins, each at distinct site. 
Serotypes A, Ci and E cleave the SNAP -25 molecule. Serotypes 
B, D, F and G cleave synaptobrevin.
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Figure 1.7
When acetylcholine is no longer able to be released, the nerve impulses 
no longer make the muscles contract. Over time, the nerve creates new 
endings in a process called sprouting. These new nerve terminals 
establish contact with the muscle and the effect of Botulinum toxin
wears off.
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1.6 RECOVERY
It is known that the effects of the botulinum toxin on acetylcholine release are 
long lasting but nevertheless temporary. Recovery occurs through regrowth. 
The end of the axon sprouts new pseudopodia which form into additional 
motor end plates.
Sprouting is rapid and but transitory because a second phase of the recovery 
process occurs with a return of synaptic activity to the original nerve terminals.
This repair process takes place over about 3 to 6 months.
de Paiva A, Meunier FA, Molgo J, et al. 1999, showed in a study involving 31 
Injections of BTX-A into the sternomastoid muscle of mice, the formation of 
terminal nerve sprouts from the parent terminal. The sprouts formed functional 
synapses with the muscle but eventually regressed at a time when the parent 
nerve terminal regained the ability to release neurotransmitters 41.
It has been shown in both experimental animals and humans, long-term 
exposure to toxin causes reversible denervation atrophy 42‘45. Alderson 
examined muscle-nerve interactions in the orbicularis oculi for treatment of 
blepharospasm 46. They found noncollateral sprouting that often ran parallel to 
muscle fibres and originated from three sources:
1. The nodes of ranvier of myelinated parent pre-terminal axons.
2. the unmyelinated terminal axon immediately proximal to the end plate; 
and
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3. the ultraterminal axonal arborisation over the end plate
In addition some nerve plates appear segmented, with each segment 
innervated by an axonal process from the same motor axon. In some cases, 
more than one end plate was present on a single muscle fibre, each 
innervated by axonal processes from different preterminal axons. No necrosis 
or inflammation has been observed in human studies47.
It remains to be seen whether similar processes occur in autonomic nerves 
innervating the lower urinary tract.
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1.7 IMMUNOGENECITY
As is the case with many medications, some patients fail to respond to 
botulinum toxin when it is first administered. This can be termed a primary 
non-response. Tachyphylaxis can also develop giving a secondary response 
failure and this is known to have, at least in part, an immunological origin. 
Primary non-response has yet to be characterised so an antibody mediated 
reaction has not yet been excluded.
Botulinum toxins are peptides and will therefore exhibit immunogenic 
properties which are significant. Resistance has been attributed to antibodies 
directed against the toxin. Repeated use, particularly in high dose, has been 
associated with resistance arising from the development of neutralising 
antibodies 48'50. Resistance is characterised by the absence of muscle 
weakness after injection.
Botulinum toxin preparations used therapeutically contain several antigenic 
proteins, in addition to the toxin itself. By no means have all of the antibodies 
formed had the ability to neutralise the therapeutic activity of the toxin. An 
antibody may be directed against an epitope that is found in a non-essential 
domain. Several laboratory generated monoclonal antibodies have been 
shown to react with botulinum toxin molecules without neutralising activity.
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The botulinum toxin serotypes, were characterised by their antigenic 
properties. Botulinum toxins are large molecules with significant homology 
amongst serotypes. Although several antibodies that cross react with different 
types of botulinum toxin have been generated in the laboratory, there have 
been no reports of neutralising activity among antibodies that cross-react with 
different botulinum toxins serotypes. Botulinum toxins A and B have significant 
homology and exhibit a set of cross-reacting antibodies. To date the cross­
reacting antibodies have not been found to show neutralising properties.51'56. 
Nevertheless it would be unwise to assume that such an occurrence were 
impossible.
Brin et al enrolled 77 patients suffering from cervical dystonia who had 
developed resistance to Botulinum toxin type-A into a 16-week, single 
treatment, double-blind, placebo controlled trial of Botulinum toxin type B. 
Improvements in severity of disability and pain were documented in the 
Botulinum toxin type B-treated patients 57.
Brashear et al enrolled 109 patients with cervical dystonia, who had manifest 
primary resistance to botulinum toxin type A, in a 16-week, randomised, multi 
center, single-treatment, double-blind, placebo controlled trial of Botulinum 
toxin type B. Placebo or 5,000 U or 10,000 U of the toxin were used. 
Significant improvements in pain, disability, and severity of cervical dystonia 
occurred for patients who were treated with botulinum toxin B as opposed to 
the placebo. The authors concluded that botulinum toxin B was safe and
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efficacious at 5,000 U and 10,000 U for the management of patients with type 
A-responsive dystonia 58.
It has been shown that more frequent injections and higher doses per booster 
session contributed to a greater risk for antitoxin antibody formation 59 61.
However, more recently, Jankovic et al in their study on patients with cervical 
dystonias demonstrated a very low immune response and antibody formation 
using a newer formulation of Botulinum toxin A 62. This contained less of a 
plethora of different proteins.
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1.8 THERAPEUTIC USES OF BOTULINUM TOXIN
1.8.1 BOTULINUM TOXIN AND MOVEMENT DISORDERS
In 1968 Edward Schantz, an American army officer, working with the type A 
toxin, was approached by Alan Scott, an ophthalmic surgeon. Schantz and 
Scott collaborated in developing BTX-A and used it successfully in correcting 
strabismus in experimental monkeys. Progress in humans was slowed by a 
treaty in 1972 banning research into biological weapons, and it was not until
some years later that USA Food and Drug Administration approval was given 
for civilian research on human volunteers. The first publication on the use of 
BTX-A in humans was in 1980 5.
Over the last two decades, the use of BTX-A has become widespread in the 
treatment of various disorders of muscle overactivity. It is now licensed in the 
UK to treat strabismus, spasmodic torticollis, blepharospasm, hemifacial 
spasm and paediatric cerebral palsy and spasticity. However, numerous other 
unlicensed applications have been reported, including oesophageal spasm, 
sphincter of Oddi dysfunction in the gastrointestinal tract, cosmetic facial 
wrinkle reduction, palmar hyperhydrosis and hypersalivation, to name but a 
few 63. The use of the agent in cosmetic treatments has attracted considerable 
public interest.
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1.8.2 BOTULINUM TOXIN AND LUTS
1.8.2.1 Botulinum toxin and Neurogenic detrusor overactivity (NDO) and 
Idiopathic Detrusor overactivity (IDO)
In 2000 Schurch et al published their results with intradetrusor injections in 31 
neurologically impaired patients. These patients with traumatic spinal cord 
injury emptied the bladder by intermittent self-catheterization. These patients 
had severe detrusor hyperreflexia and incontinence despite a high dose of 
anticholinergic medication. Under cystoscopic control a total of 200 to 300 
units of botulinum-A toxin were injected into the detrusor muscle at 20 to 30 
sites (10 units per ml. per site), sparing the trigone. Pre-treatment evaluation 
included a clinical examination and complete urodynamic investigation They 
reported a significant improvement in all urodynamic variables and post void 
residual volumes. Improvement in urodynamic variables and incontinence was 
present in all patients re-evaluated at 16 and 36 weeks 64.
In 2003, the same author reiterated that the preliminary results of intradetrusor 
injections of Botulinum toxin A in neurogenic detrusor overactivity were 
promising, however the optimum dose of the toxin required for this indication 
was not yet known. It was concluded that botulinum toxin injection into either 
the external urethral sphincter or the detrusor offered promise for many 
different urological dysfunctions. Nevertheless evidence from proper
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controlled trials was required to justify the role of botulinum-A toxin injections 
in the fields of urology and neurourology 65.
Ten European medical centres published the results from 231 patients with 
neurogenic detrusor overactivity who were treated with BTX-A. 300 units of 
Botulinum toxin A were injected cystoscopically into the detrusor muscle at 30 
different locations, while sparing the trigone. Urinary continence status, 
concomitant anticholinergic medication use, and patient satisfaction were 
recorded. Key urodynamic variables at baseline and at the first and second 
urodynamic follow-up examinations were analysed. This retrospective 
European multicentre study, presented an extensive experience with BTX-A 
injections into the detrusor muscle to treat neurogenic incontinence due to 
detrusor overactivity. The data supported safety and efficacy but being non­
comparative and unblinded interpretation must be extremely guarded 66.
A team of Italian researchers, in March 2004, published a study of seventy- 
five patients with spinal cord injury and refractory detrusor overactivity. Of 
these, 35 patients received repeated intravesical instillations of resiniferatoxin 
(RTX) dissolved in normal saline; 40 patients received repeated injections of 
300 units Botulinum toxin A diluted in 30 ml normal saline. Clinical 
assessment and urodynamics were performed at baseline and 6, 12 and 24 
months after treatment. This study was neither blinded nor randomised. It was 
observed that intravesical RTX and botulinum-A toxin injections into the 
detrusor muscle was associated with improvement in symptoms and increase
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in bladder capacity on urodynamic testing. Patients receiving Botulinum-A 
toxin injection showed greater clinical benefit and urodynamic change than 
intravesical RTX 67 ’ 68. The trial design pleads caution. It should be noted that 
when RTX was submitted to double-blind, randomised, placebo-controlled 
scrutiny, efficacy was not detected.
In May 2004, Kuo et al investigated the urodynamic changes after detrusor 
injection of botulinum A toxin in 30 patients with detrusor overactivity 
refractory to treatment with anticholinergic agents. This was an open non­
comparative, observational study. 200 U of Botulinum toxin A was injected at 
40 sites in the detrusor. Urodynamic variables and symptom scores were 
assessed at baseline and 2 weeks and 3 months after the injections. The 
conclusions, disproportionate to the design, were that Intradetrusor injection of 
200 U of BTX-A was effective in the treatment of detrusor overactivity that 
was refractory to anticholinergic agents and that the therapeutic effects lasted 
for 3 to 9 months (mean 5.3) 69.
An open, uncontrolled study in Scandinavia recruited fifteen patients suffering 
from NDO. The volume of urine leakage during episodes of incontinence was 
quantified, and filling cystometry was performed before and after BTX-A 
treatment. 300 IU of BTX-A was injected cystoscopically into the detrusor 
muscle, excluding the trigone region. The cystometry was interpreted as 
showing increase in bladder capacity and marked reductions in detrusor 
pressures after treatment, this being seen as proof of efficay.70. The
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Laplacian relationship between pressure and volume (Pressure = 2 x Tension 
/ Radius) means that if the bladder increases a contraction of similar force but 
at higher capacity will generate a lower pressure.
Researchers from Chicago University included thirty-five patients (29 women 
and 6 men) with idiopathic detrusor overactivity, who had failed anticholinergic 
therapy, in another open, uncontrolled study and injected 300 U of BTX-A 
injected transurethrally at 30 sites within the bladder. Patients were evaluated 
at 3 weeks and 6 months after treatment by completion of the short forms of 
the Incontinence Impact Questionnaire (IIQ-7) and the Urogenital Distress 
Inventory (UDI-6), as well as questions assessing global response to the 
treatment. A change in symptoms, associated with detrusor overactivity, that 
lasted for at least six months was reported and attributed to the drug.71
A lower dose of 150 U of Botulinum toxin A was used in an open, 
uncontrolled, study at the Duke University in North Carolina. Patients with 
evidence of urge urinary incontinence on 3-day bladder diary, a 24-hour pad 
weight of 100 gm or greater, absent or minimal stress leakage, absent 
detrusor dysfunction, and a history of failed anticholinergic and physical 
therapies were included. Evaluations were performed at 2 weeks, 6 weeks, 3 
months and 6 months after injection and outcome measures included daily 
incontinence episodes, Urogenital Distress Inventory and the Incontinence 
Impact Questionnaire, 24-hour pad weights, daily pad usage and urinalysis at
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all visits. They reported decreased urge urinary incontinence and improved 
quality of life for 3 months after injection 72
A lower dose of 100U of BTX-A was used in an open uncontrolled study of 26 
women with idiopathic detrusor overactivity (IDO) in Switzerland. BTX-A was 
injected into the detrusor muscle at 30 sites. Clinical and urodynamic 
evaluations and a quality of life assessment were performed at baseline and 
4, 12, and 36 weeks after BTX-A treatment. Of 26 women, 14 were dry after 4 
weeks, 13 of 20 women after 12 weeks, and 3 of 5 women after 36 weeks.
Two women failed to respond.73
Schulte et al, in July 2005, investigated the effect of BTX- A bladder injections 
in the treatment of overactive bladder syndrome in the absence of detrusor 
overactivity. The patients were 7 women (average age 61.1 years, range 51 to 
79) who presented with overactive bladder symptoms. Their disorder had 
been refractory to several classic treatment options. Urodynamic examination 
excluded detrusor overactivity. A total of 300 U BTX-A was injected, of which 
50 to 75 U was injected as quadrant injections into the external sphincter 
muscle to avoid the postoperative need for catheterization in the case of high 
post void residual urine volume. For follow-up, complete urodynamic studies 
were performed, and a bladder diary and validated incontinence 
questionnaires were given to patients at all visits at 1, 3, and 6 months. The 
bladder diaries indicated a reduction in daytime frequency and nocturia and a 
reduction in pad use. The maximal voiding volume increased. The urodynamic
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examinations showed an increase in volumes when the first and the strong 
desire to void were expressed. The maximal bladder capacity increased. In 
the questionnaires, 5 of the 7 patients reported better urine control after 
therapy, and 6 would have chosen this therapy again for their condition. This 
study was open and uncontrolled.74
Kuo et al. studied twenty patients with idiopathic detrusor overactivity 
refractory to anticholinergics. They were treated with injection of 200 U BTX-A 
into the suburothelial space and the clinical effects on the lower urinary tract 
symptoms and urodynamic variables were assessed. After these injections 
the 15 patients described hesitancy in initiation of voiding and difficult 
urination but also noted fewer OAB symptoms overactivity.75
A comparison between the response of patients with idiopathic detrusor 
overactivity and neurogenic detrusor overactivity to intradetrusor injection of 
BTX-A was made in a study at the Institute of Neurology, London. In this, 
open study, a total of 44 patients with spinal NDO and 31 with IDO who had 
urgency, and/or urgency incontinence, with detrusor overactivity on 
urodynamics, received 300 units (NDO) or 200 units (IDO) of BTX-A injected 
into the bladder with a minimally invasive outpatient technique. Urodynamic 
maximum cystometeric capacity and maximum detrusor pressure during 
filling, urinary frequency, incontinence episodes and urgency episodes from 4- 
day voiding diaries were compared between the 2 groups at baseline and for 
differences in change at 4 and 16 weeks after treatment. The authors
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concluded that the patients with intractable I DO respond to intradetrusor BTX- 
A with similar changes in urodynamic variables and lower symptoms to those 
with spinal NDO. This was despite the lower dose of toxin used. 76
Klaphajone et al reported a case series of ten patients with neurogenic 
detrusor overactivity combined with low-compliance bladder due to spinal cord 
lesions. 300U of BTX-A was injected into the detrusor muscle.. Urinary 
continence, functional bladder capacity, bladder compliance, detrusor 
contraction pressure, and volume at first reflex voiding were assessed. 
Measurements were taken before and 6, 16, and 36 weeks post treatment.
Six weeks after treatment, complete continence was restored in 7 patients 
without oxyphencyclimine. Mean functional bladder capacity and compliance 
significantly increased, whereas maximal detrusor contraction pressure 
significantly decreased. Urodynamic variables remained significantly improved 
at 16 weeks, but values were returning toward baseline levels by 36 weeks.77
There is evidence that BTX-A may affect sensory fibres as well as motor. This 
was investigated in humans by studying the sensory receptors P2X3 and 
TRPV1 in detrusor biopsies from patients with neurogenic or IDO at the 
Hammersmith Hospital, London. Tissue was obtained at 4 and 16 weeks after 
injection with BTX-A from 38 patients (22 with neurogenic DO, 16 with 
idiopathic DO). Specimens were studied immunohistochemically for P2X3, 
TRPV1 and the pan-neuronal marker PGP9.5, in comparison with controls. 
P2X3-immunoreactive and TRPV1-immunoreactive (-IR) fibers were
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decreased at 4 weeks after BTX-A, and more significantly at 16 weeks, when 
significant improvements were observed in clinical and urodynamic variables. 
P2X3-IR fiber decrease was significantly correlated with reduction of urgency 
episodes at 4 and 16 weeks, but not maximum cystometric capacity or 
detrusor pressures. TRPV1-IR fiber decrease showed a similar trend. 
PGP9.5-IR suburothelial fibers remained unchanged after treatment at both 
follow-ups.78. No control samples were included in the analysis.
The problem with all of these studies is that they did not use controls and the 
patients were not randomised. This situation usually arises because of the 
adoption of a treatment option in clinical practice that is then scrutinised post- 
hoc by retrospective analysis of the data. Some other factor may have led to 
the change in patient circumstance. A plausible argument offered in defence 
is that if open uncontrolled data be published from many different centres with 
complimentary results then the probability of accuracy increases. This is true 
but involves a small increase from a low starting probability.
The use of urodynamic as an outcome measure presents difficulties. In all the 
RCT published literature of the treatment of the overactive bladder where 
urodynamics has been used as an outcome measure the two variables which 
have been consistently reported to change for the better are the bladder 
capacity and the detrusor pressure. The change in detrusor pressure is a 
function of Laplacian physiology and therefore an epiphenomenon of the test. 
Bladder capacity can be assessed with a measuring jug and a frequency
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volume chart. Where urodynamic findings have been compared with the 
patients experience of the disease correlations have failed to materialise.
The first randomised placebo-controlled trial measuring the safety and efficacy 
of BTX-A in neurogenic detrusor overactivity was published by Schurch et al 
in July 2005 in the report of a 6 month study. A total of 59 patients with urinary 
incontinence caused by neurogenic detrusor overactivity (due to spinal cord 
injury in 53 and multiple sclerosis in 6) requiring clean intermittent self­
catheterization were randomised to receive a single dose into the detrusor of 
BTX-A (200 U or 300 U) or placebo. Changes in daily frequency of urinary 
incontinence episodes were monitored via a patient bladder diary during 24 
weeks. Urodynamic measures of maximum cystometric capacity, reflex 
detrusor volume, and maximum detrusor pressure were used to assess 
treatment effect. Quality of life was assessed with the Incontinence Quality of 
Life questionnaire. There were significant post treatment differences in 
decreases in incontinence episodes from baseline in the 2 BTX-A groups 
compared to the placebo group. Positive treatment effects were also reflected 
by significant differences in change in bladder capacity and in patient quality 
of life. The differences in change were observed from the first evaluation at 
week 2 to the end of the 24-week study.79
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1.8.2.2 Botulinum toxin and detrusor sphincter dyssynergia (DSD)
Sphincter injection of BTX A was first described in 5 patients with detrusor 
sphincter dyssynergia (DSD) by Dykstra et al in 1990. . The sphincter was 
injected with either a low dose of BTX A toxin or normal saline once per week 
for three weeks. Electromyography of the external urethral sphincter indicated 
denervation in the three patients who received toxin injections. The urethral 
pressure profile decreased an average of 25cm of water; post voiding residual 
volume of urine decreased an average of 125cc, and bladder pressure during 
voiding decreased to an average of 30cm of water. In the two patients who 
received normal saline injections, parameters were unchanged from baseline 
values until subsequent injection with BTX A toxin once per week for three 
weeks when their responses were similar to those of the other three patients. 
The duration of the toxin's effect averaged two months.
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Schurch et al (1996) studied 24 spinal cord injury male patients with detrusor- 
sphincter dyssynergia. Transurethral and transperineal BTX A injections were 
performed and compared for efficacy. In 21 of 24 patients detrusor-sphincter 
dyssynergia was significantly improved with a concomitant decrease in post­
void residual volumes in most cases. BTX A effects lasted 3 to 9 months.81
de-Seze et al conducted a double-blind lidocaine-controlled study in 13 
patients with detrusor sphincter dyssynergia spinal cord disease.
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Thirteen patients (1 female and 12 male) suffering from chronic urinary 
retention due to DSD were randomised to receive one transperineal injection 
of 100 IU BTX A or 4 ml of 0.5% lidocaine. The main criteria of efficacy were 
post-voiding residual urine volume, assessed three times daily on day one, 
day 7 and day 30 after each injection. Other criteria were micturition diary, 
satisfaction score, maximal urethral pressure, maximum detrusor pressure 
and type of DSD, recorded on day 0 and day 30. In, there were significant 
between group differences in change in post-voiding residual urine volume, 
maximal urethral pressure, favouring the BTX A group. Symptom score was 
higher in BTX-A group than Lidocaine group.82
A case series was reported from Russia on 9 patients (6 males and 3 
females) with detrusor sphincter dyssynergia. Transperineal injection of 100 
units of BTX- A was used under electromyographic control into the external 
urethral sphincter. Abdominal pressure fell from 75 to 39 cm, on the average; 
maximal detrusor pressure fell from 59 to 29 cm, and mean maximal urinary 
flow rate rose from 4.3 to 9.6 ml/s..83
An account of 6-years experience using BTX A in the bladder and urethra in 
110 patients for a variety of lower urinary tract disorders was published in 
2005. Of these 68 patients with detrusor sphincter dyssynergia were injected 
100 to 200 U of BTX-A in 4 mL divided in equal doses into the four quadrants 
of the external sphincter, transurethrally. Two women with multiple sclerosis 
and mild baseline stress urinary incontinence reported increased leakage with
stress after BTX-A external sphincter injection, and one woman with multiple 
sclerosis noted new onset stress urinary incontinence after external sphincter 
injection. However, they all reported significant improvement in post void 
residual urine volume, uroflow, urge incontinence, and frequency.84
1.8.2.3 Paediatric uses of Botulinum toxin
The established treatment of children with neurogenic bladder consists of the 
use of anticholinergic drugs, such as oxybutynin and tolterodine, and clean 
intermittent catheterization four or five times a day.
Schulte et al in 2002 studied BTX A in children with detrusor hyperreflexia due 
to myelomeningocele. The case series were 17 children (average age 10.8 
years) who had detrusor hyperreflexia and were using clean intermittent 
catheterization four or five times a day. Urodynamic studies were followed by 
injection of 85 to 300 U of BTX A into 30 to 40 sites in the detrusor muscle. 
Urodynamic follow-up was done 2 to 4 weeks after injection. A significant 
increase was seen in mean reflex volume, maximal bladder capacity and 
detrusor compliance. This was accompanied by a decrease in the detrusor 
pressures.85,86
Further results were published by the same group in 2003. 20 Children with 
hyper-reflexive detrusor muscle and high bladder pressure, over 40 cm H20  
despite anticholinergic therapy were recruited for this study. After baseline
urodynamic measurements, they were injected BTX A into the detrusor 
muscle at 30-50 sites at 12 U/kg of body weight up to a maximum of 300 U.
All the urodynamic parameters showed a significant improvement.87
Recently, Schulte et al assessed the long-term success of treatment with 
repeated BTX A injections into the detrusor muscle for neurogenic detrusor 
overactivity in children. The charts of 10 children (average age at first injection
11.2 years) with neurogenic detrusor overactivity were reviewed who had 
received at least three BTX A detrusor injections; four had received five or 
more injections. The total dose of BTX A was 85 to 300 U. d the urodynamic 
outcomes 6 months after each injection were measured and the results after 
the first injection compared with the results after the third and fifth injections. It 
was observed that there was a sustained improvement in all the urodynamic 
measures after repeated BTX A detrusor injections in children with neurogenic 
bladder.88
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1.8.2.4 Botulinum toxin and benign prostatic obstruction
To expand the clinical use of BTX A in lower urinary tract dysfunction, an 
attempt has been made to study its clinical applications in benign prostatic 
hyperplasia (BPH).
In a prospective study, Kuo assessed the effectiveness of prostate injection of 
BTX A in patients who were poor surgical candidates. Ten patients with BPH 
and urinary retention or a large post void residual urine volume received 200 
U botulinum A toxin injection into the transition zone of the prostate. The 
clinical results and urodynamic varaibles at baseline and after treatment were 
compared. All patients had an improvement in spontaneous voiding after 
treatment. Of them, 8 had an excellent result and 2 had an improved result. 
Both voiding pressure and post void residual volume were significantly 
decreased after treatment. The total prostate volume was significantly 
reduced, and the maximal flow rate was significantly increased after 
treatment. The maximal effects of BTX A appeared at about 1 week and were 
maintained at 3 and 6 months after treatment. At 6 to 12 months (mean 9) of 
follow-up, no patient had had recurrence of urinary retention and the voiding 
condition in all patients remained at the post-treatment status.89
Subsequently, sixteen men with symptomatic BPH in small prostates (prostate 
volume less than 30 cm3), peak flow rate less than 12 mL/s and with 
refractory disease after at least 1 month of alpha-blocker treatment received
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BTX A 100 U injection into the prostate transperineally under transrectal 
ultrasound guidance. The clinical effects were evaluated at baseline and after 
treatment. All patients reported subjective improvement starting at 
approximately 1 week and achieved a maximal effect after 1 month that was 
maintained at 3 and 6 months. At 6 to 12 months (mean 10) of follow-up, no 
patient had symptom recurrence. The mean prostate volume, symptom score, 
and quality-of-life index were significantly reduced.90
1.8.2.5 Botulinum toxin and Interstitial cystitis
There is some evidence that BTX A might have analgesic properties. Chuang 
et al in 2004 investigated the effect of intravesical BTX A administration on 
afferent nerves of the bladder containing calcitonin gene-related peptide 
(CGRP) immunoreactivity. The study bladders were hyperactivity from an 
acetic acid induced bladder pain model in rats. Experimental and control 
animals were catheterized and intravesically exposed to protamine sulfate (1 
ml, 10 mg/ml), followed by BTX A (1 ml, 25 U/ml) or saline, respectively.
Three or 7 days after intravesical therapy continuous cystometrograms were 
performed using urethane anaesthesia by filling the bladder with saline, 
followed by 0.3% acetic acid. Bladder immunohistochemistry was used to 
detect CGRP. The intercontraction interval (ICI) was decreased after acetic 
acid instillation in the control group at days 3 and 7, respectively. However, 
rats that received BTX A showed a significantly decreased response to acetic 
acid instillation at day 7. This effect was not observed at day 3. Increased
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CGRP immunoreactivity was detected in the BTX A treated group at day 7, 
which was not detected at day 3. Intravesical BTX A administration blocked 
acetic acid induced bladder pain responses and inhibited CGRP release from 
afferent nerve terminals. The authors made the claim that their data supported 
the clinical application of BTX-A for the treatment of interstitial cystitis.91
Smith et al presented clinical evidence from the use of BTX-A suggesting an 
antinociceptive role in patients with interstitial cystitis (IC). Thirteen female 
patients (6 in the United States and 7 in Poland) with IC according to the 
criteria of the National Institute of Diabetes, Digestive and Kidney Disease 
were included. 100 to 200 U BTX A was injected through a cystoscope into 20 
to 30 sites submucosally in the trigone and floor of the bladder. Patients were 
evaluated with the O'Leary-Sant validated IC questionnaire or with voiding 
charts and a visual analog pain scale 1 month postoperatively and at 
subsequent 3-month intervals. Overall, 9 (69%) of 13 patients noted 
subjective improvement after BTX A treatment. The Interstitial Cystitis 
Symptom Index and Interstitial Cystitis Problem Index mean scores improved. 
Daytime frequency, nocturia, and pain by visual analog scale decreased and 
the first desire to void and maximal cystometric capacity increased. The 
authors proposed that BTX A may have had an antinociceptive effect on 
bladder afferent pathways in patients with IC, producing both symptomatic 
and functional improvements.92
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By contradistinction, a recent report describes eight women and two men with 
chronic interstitial cystitis who had failed conventional treatments. They were 
enrolled in a study by Kuo in Taiwan. In 5 patients, 100 units of BTX A was 
injected suburothelially into 20 sites, and an additional 100 units were injected 
into the trigone in the other 5 patients. Therapeutic outcome including 
functional bladder capacity, number of daily urinations, bladder pain, and 
urodynamic changes were compared between baseline and 3 months after 
treatment. The clinical result of suburothelial BTX A injection was 
disappointing. None of the patients was symptom free and only a limited 
improvement in bladder capacity and pain score was achieved in 2 patients.93
Several publications have reviewed the applications of Botulinum toxin in the 
lower urinary tract. They conclude, on the available data, that intradetrusor 
injections of Botulinum toxin might become a standard therapeutic option in 
patients with neurogenic or non neurogenic detrusor overactivity, who do not 
respond to or do not tolerate anticholinergic medication. It might also be 
expected to improve bladder emptying in patients with dysfunctional voiding 
problems such as detrusor sphincter dyssynergia. However, the lack of 
placebo control and proper comparative design makes these conclusions 
optimistic.
To reach firmer conclusions, controlled studies with well defined patient 
populations and using validated and reproducible outcome measures are 
needed. In addition, information on repeated injections over a longer period of 
time is required.94'106
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1.9 BOTULINUM TOXIN B
1.9.1 UNIQUE FEATURES
The Botulinum toxin B evokes particular interest because of the following:
• A Smaller molecular weight (5000-7000) as compared to Botulinum 
toxin A (9000)
• High stability at room temperature (25°)
• It does not need to be lyophilised (theoretically more potent)
• More even diffusion J
• It provides a useful alternative to Botulinum toxin type A in primary and 
secondary non responders i.e. the patients who develop immunity 
against the type A toxin because of repeated injections.
• Owing to its smaller size and different diffusion characteristics there is 
a theoretical possibility of delivering this drug by some other means 
rather than injections.
• Last but not the least, there is a chance of it being more cost effective 
because the properties may allow the use of less at a reduced 
frequency of injections18,107.
More rapid onset of action As compared to 
Botulinum toxin A
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1.9.2 Botulinum toxin B and LUTS
Botulinum toxin type B (BTX B) has been little studied in lower urinary tract 
symptoms. The unique immunogenicity of the various serotypes of the toxin, 
along with the fact that both toxins interact with different target proteins means 
that BTX B has therapeutic potential in patients unresponsive to BTX A 
particularly those who have become resistant after repeated injections, 
consequent upon the antibody response 108,109.
The first urological use of BTX B was reported as a case study published by 
Dykstra et al in which a patient with detrusor hyperreflexia was successfully 
treated with 2 separate injections of 5000U and 7500U of BTX B into the 
detrusor. The result of each treatment lasted for four months 11°.
An open label dose escalation study of 15 female patients with overactive 
bladder demonstrated average action duration of 43 days with 5000U. The 
BTX B doses used in this study were 2500, 3750, 5000, 10000 and 15000 
units. All but one patient responded with decreased frequency, urgency and 
no incontinence. The degree of response was similar across all doses; 
however, the duration of response was dose dependent111.
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Recently, a case report by Reitz and Schurch demonstrated successful 
management of two cases of neurogenic detrusor activity with BTX B 
injections who were resistant to BTX A 109.
In another study, done on the effects of Botulinum toxins in the treatment of 
palmar and axillary hyperhydrosis, it was shown that type B clearly produces a 
more rapid onset of effect than type A, and appears to diffuse more evenly in 
some injected muscles. This may permit a reduction in the number of injection 
sites required and may provide a smoother and more even clinical effect in 
some areas 112.
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Chapter 2 DETRUSOR OVERACTIVITY AND VARIOUS TREATMENT 
MODALITIES
2.1 ICS NOMENCLATURE
Since all the patients recruited in our study had detrusor overactivity, it is 
necessary to discuss the nomenclature related to this condition.
In everyday life the individual attempts to inhibit detrusor over activity until he 
or she is in a position to void. Therefore, during cystometery, when the aims of 
the filling study have been achieved, and when the patient has a desire to 
void, normally the ‘permission to void’ is given. That moment is indicated on 
the Urodynamic trace and all detrusor activity before the permission to void is 
defined as ‘involuntary detrusor activity’.
Normal detrusor function allows the bladder filling with little or no change in 
pressure. No involuntary phasic contractions occur despite provocation.
Detrusor overactivity is a urodynamic observation characterised by 
involuntary detrusor contractions during the filling phase which may be 
spontaneous or provoked. This may also be qualified, when possible, 
according to cause, as:
Neurogenic detrusor overactivity, earlier known as detrusor hyperreflexia, 
when there is a known neurological condition.
Idiopathic detrusor overactivity, earlier known as detrusor instability, when 
there is no defined cause.
Other relevant terms that are often used in this context are:
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Phasic detrusor overactivity is defined by a characteristic waveform and 
may or may not lead to urinary incontinence.
Terminal detrusor overactivity is defined as a single, involuntary detrusor 
contraction, occurring at cystometeric capacity, which cannot be suppressed 
and results in incontinence usually resulting in bladder emptying.
Detrusor overactivity incontinence is incontinence due to an involuntary 
detrusor contraction 113.
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2.2 DETRUSOR OVERACTIVITY-MANAGEMENT
There are several different approaches that may be used in managing and 
treating urge incontinence. If evidence of infection is found in urine culture, 
antibiotics will be prescribed. The choice of a specific treatment will depend on 
the severity of the symptoms and the extent that the symptoms interfere with 
your life style. There are three main approaches to treatment: medication, 
retraining, and surgery.
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2.2.1 MEDICATION
Medications used to treat urge incontinence are aimed at relaxing the 
involuntary contraction of the bladder and improving bladder function. There 
are several types of medications that may be used alone or in combination:
✓ anticholinergic agents (oxybutynin, tolterodine)
✓ tricyclic antidepressants (imipramine)
Oxybutynin and tolterodine are antispasmodic medications that relax the 
smooth muscle of the bladder. These are the most commonly used 
medications for urge incontinence and are available in a once-a-day 
formulation that makes dosing easy and effective114'121. Side effects of 
oxybutynin and tolterodine are minimal, with the most common being dry 
mouth and constipation. However, these medications cannot be used by 
patients with narrow angle glaucoma.
Anticholinergic medications block inappropriate contractions of the bladder. 
They were widely used in the past to treat urge incontinence because they are 
relatively inexpensive yet effective. Oxybutynin and tolterodine have virtually 
replaced the use of these medications because they have fewer side effects
122-125
Tricyclic antidepressants have also been used to treat urge incontinence 
because of their ability to inhibit or "paralyse" the bladder smooth muscle. 
Possible side effects include fatigue, dry mouth, dizziness, blurred vision,
119, 121, 126nausea and insomnia
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2.2.2 SURGERY
When conservative and pharmacologic treatments for detrusor overactivity 
incontinence fail, there are a number of surgical procedures that can be 
performed for the patient who is significantly bothered by his or her symptoms. 
Surgical treatments include sacral nerve neuromodulation, bladder 
denervation, autoaugmentation and bladder augmentation (lleocystoplasty)127'
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Sacral Neuromodulation
Sacral nerve stimulation is performed in two stages: stage I, a clinical trial of a 
temporary or permanent lead for external stimulation; and stage II, 
implantation of a subcutaneous implantable pulse generator (IPG). Each 
stage can be performed with monitored anaesthesia care supplemented by 
local anaesthesia. During the initial introduction of sacral neuromodulation 
therapy, patients underwent a percutaneous nerve evaluation by the 
placement of a unilateral percutaneous lead in the S3 foramen with use of 
local injectable anaesthesia. The lead was connected to an external pulse 
generator and worn by the patient for several days. A large number of false- 
negative results with therapy are attributed to improper lead placement and 
migration. Whereas some physicians still prefer to perform the first stage by a 
percutaneous nerve evaluation approach, most have adopted a permanent
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lead placement for the first stage in an attempt to avoid the issues related to 
high false-negative results with the first stage and high false-positive results 
with the second stage. Changes in lower urinary tract symptoms and post void 
residuals are recorded in a detailed bladder diary. If improvement is minimal 
or absent, revision or bilateral percutaneous lead placement may be 
attempted. If more than 50% improvement in symptoms of urgency-frequency 
or urge incontinence is attained, a permanent IPG is implanted. The length of 
the trial with the external pulse generator may vary slightly from patient to 
patient, by the indication, and by the surgeon's practice preference.
Schmidt and co-workers (1999) reported on SNS therapy in 76 patients with 
refractory urge incontinence from 16 centres worldwide randomized to active 
or delayed therapy (control group) during the study period of 6 months. Of the 
34 patients receiving active SNS therapy compared with the delayed group,
16 (47%) were completely dry, and an additional 10 (29%) demonstrated 
more than 50% reduction in incontinence episodes. Complications were IPG 
site pain in 16%, implant infections in 19%, and lead migration in 7%134.
In a similar study design, Hassouna and colleagues (2000) reported the 
outcomes of SNS on refractory urgency-frequency conditions in 51 patients 
randomized from 12 centres during an initial 6-month period that was 
extended to 2 years. Outcomes at 6 months in the active SNS group showed 
improvement in the number of daily voids (16.9 ± 9.7 to 9.3 ± 5.1), volume 
voided (118 ± 74 mL to 226 ± 124 ml_), degree of urgency (rank score of 2.2 ±
0.6 to 1.6 ± 0.9), and SF-36 quality of life measures. At 6 months after
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implantation, stimulators in the active group were turned off and urinary 
symptoms returned to baseline values. After reactivation of SNS, sustained 
efficacy was documented at 12 and 24 months135.
Denervation Procedures
Denervation techniques include bladder transection and reattachment, either 
by open surgery or endoscopically; complete S2 to S4 rhizotomy; partial 
rhizotomy; and subtrigonal phenol or alcohol injections. There is little 
documentation of long-term efficacy of these denervation procedures, and 
many of the techniques are associated with considerable morbidity, and, for 
practical purposes, they have been abandoned136'139 Furthermore, despite an 
initial short-term response, the long-term results are often dominated by the 
development of low bladder compliance or recurrent detrusor overactivity. 
Sacral rhizotomy is reserved for the paraplegic or quadriplegic population. 
Posterior rhizotomy may be combined with the placement of a neurostimulator 
on the anterior nerve roots to inhibit involuntary contractions and stimulate 
spontaneous voiding. In 1959, Ingelman-Sundberg described a transvaginal 
technique intended to accomplish partial denervation of the subtrigonal nerve 
supply to the bladder by selectively dividing the preganglionic nerves near the 
inferior surface of the bladder through a transvaginal incision. Several authors 
have reported success 140 141, but outcome measures have included mostly 
patients' assessments done in a retrospective fashion. Thus, the procedure 
has never gained acceptance.
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Autoaugmentation of the bladder
Autoaugmentation of the bladder was initially described by Cartwright and 
Snow (1989) as an alternative to enterocystoplasty in children with 
neuropathic bladder142.
Autoaugmentation may be performed by incision (detrusor myotomy) or 
excision (detrusor myectomy) of a portion (usually the anterior, lateral, and 
superior surface) of the detrusor muscle. Either technique creates a mucosal 
bulge or pseudodiverticulum, which should increase capacity and decrease 
storage pressure.
There have been several reports of successful short-term outcomes after 
detrusor myectomy in children142 and in adults with neuropathic bladder143. 
However, longer term follow-up in children 144 and adults with non-neurogenic 
urge incontinence 145showed disappointing results.
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Augmentation Cystoplasty
Augmentation cystoplasty increases bladder capacity and decreases detrusor 
overactivity by enlarging the bladder with the addition of a bowel segment and 
possibly by disrupting the detrusor. In a large majority of patients with 
refractory detrusor overactivity, augmentation enterocystoplasty is effective, 
provided that these basic principles are followed: (1) the intestinal segment is 
detubularized by incising the antimesenteric border, (2) the segment is 
reconfigured into the approximate shape of a half-sphere, (3) a wide 
anastomosis between the reconfigured bowel and the bladder is performed, 
and (4) a large bladder capacity is achieved. Classically, augmentation 
enterocystoplasty has been performed in patients with neurogenic voiding 
dysfunction, but it has been shown to be effective for patients with neurogenic 
and non-neurogenic detrusor overactivity 146.
Many patients, however, require intermittent self-catheterization after 
augmentation and need to be prepared to do this prior to consenting to the 
operation147'148.
Complications of augmentation cystoplasty include metabolic disturbances 
(hyperchloremic acidosis), urinary tract infections, stone formation, 
perforation, and malignancy.
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2.2.3 DIET
Some experts recommend a regimen of controlled fluid intake as a 
supplement to other therapies in the management of. The goal of this program 
is to distribute the intake of fluids throughout the course of the day, so the 
bladder does not need to handle a large volume of urine at one time.
Fluid restriction has been advocated in the treatment of both SUI and OAB. 
The rationale is that abdominal leak pressures appear to be volume 
dependent; therefore, physical stress occurring at lower bladder volumes will 
be both less likely to cause incontinence and will be associated with lower 
volume loss when leakage does occur. Similarly, OAB is believed to be a 
volume-driven phenomenon, and slower filling promotes bladder compliance 
and lower pressures. This concept appears to be well accepted, as manifest 
by a recent U.S. study in which 38% of incontinent women had tried limiting 
fluids compared with 21% who tried Kegel exercises and 6% using 
prescription medications 149. On the other hand, extreme fluid restriction 
produces concentrated urine, which has been postulated to be a bladder 
irritant, leading to detrusor overactivity as well as constipation, which can 
negatively affect bladder function. Indeed, there is conflict regarding fluid 
management, with some investigators showing improvement with fluid 
reduction, whereas others finding that increasing fluid intake improved 
incontinence. It would appear that it is best to recommend a normal fluid 
consumption, reserving fluid restriction for those patients with abnormally high 
fluid intakes 15°.
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Caffeine is well known as a nervous system stimulant and has demonstrable 
effects on detrusor muscle in vitro and in vitro, promoting unstable 
contractions. In one study of community-dwelling elderly women subjects who 
decreased caffeine and increased fluid intake, increased voiding volumes and 
fewer accidents were experienced 151. High caffeine intake (>400 mg/day 
average) also correlated with urodynamic detrusor overactivity compared with 
stress-incontinent women (<200 mg/day average) 152. It has thus been 
postulated to be a cause of OAB symptoms, and caffeine reduction has been 
advised for OAB patients. Epidemiologic data are less clear. Reports usually 
break down consumption by type of beverage rather than actual caffeine 
consumption as is typically found in smaller studies of dietary intervention. 
Such small studies have typically shown a correlation between caffeine 
reduction and reduction of incontinence 151,153. Although larger studies would 
be helpful, it seems appropriate to recommend restriction, particularly in those 
patients with very high intake of caffeine.
Tea consumption correlated with urge incontinence in the EPINCONT study, 
but alcohol and coffee consumption did no t154
Additionally, it may be helpful to eliminate your intake of foods that may irritate 
the bladder, such as caffeine, spicy foods, carbonated drinks, and highly 
acidic foods such as citrus fruits and juices 151-153 , 155 , 157 , 158 . 159 ,
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2.2.4 BLADDER RETRAINING
Management of bladder over activity usually begins with a program of bladder 
retraining. Occasionally, electrical stimulation and biofeedback therapy may 
be used in conjunction with bladder retraining.
A program of bladder retraining involves becoming aware of patterns of 
incontinence episodes and relearning skills necessary for storage and proper 
emptying of the bladder. Bladder retraining alone is successful in 75% of 
people treated for urge incontinence.
Bladder retraining consists of developing a schedule of times when you 
should try to urinate, while trying to consciously delay urination between these 
times. One method is to force yourself to wait 1 to 1 1/2 hours between 
urinations, despite any leakage or urge to urinate in between these times. As 
you become skilled at waiting, gradually increase the time intervals by 1/2 
hour until you are urinating every 3 to 4 hours 159'164.
Some therapists place a sensor in the vagina (for women) or the anus (for 
men) to assess contraction of the pelvic floor muscles. A monitor will display a 
graph showing which muscles are contracting and which are at rest. The 
therapist can help you identify the correct muscles for performing Kegel 
exercises165'167.
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About 75% of people who use biofeedback to enhance performance of Kegel 
exercises report symptom improvement, with 15% considered cured168,169.
Electrical stimulation involves using low-voltage electric current to stimulate 
the correct group of muscles. The current may be delivered using an anal or 
vaginal probe. The electrical stimulation therapy may be performed in the 
clinic or at home. Treatment sessions usually last 20 minutes and may be 
performed every 1 to 4 days.
Some clinical studies have shown promising results in treating urge 
incontinence with electrical stimulation.
2.2.5 ACTIVITY
There are now epidemiologic data supporting a causal association between 
obesity and incontinence. In a 1-year longitudinal study of 6424 women older 
than 40 years of age there was a strong correlation between body mass index 
(BMI) and the risk of both OAB and SUI 170.
Other studies consistently confirm the relationship between obesity and Urge 
Incontinence171,172.
There are positive case series of morbidly obese women but only one 
published, peer-reviewed randomized study investigating the effect of weight 
loss on Ul. Subak and colleagues (2005) randomized 48 women with Ul and 
BMI between ages 25 and 45 to receive a liquid diet weight reduction program 
either immediately or after a 3-month delay. The median weight (interquartile 
range)) weight was 97 kg (87 to 106 kg), and the incontinence frequency was 
21 episodes per week (11 to 33). At the end of 3 months women in the 
immediate treatment group lost an average of 16 kg compared with 0 kg in the 
delayed group. Incontinence episodes decreased 60% in the treatment group 
compared with 15% in the controls. Improvement was seen in both SUI and 
UUI. A similar response was then seen when the delayed group was treated. 
This study suggests that all types of Ul may respond to moderate weight
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Chapter 3- METHOD 
3.1 DISCUSSION OF METHOD
Patients with detrusor over activity represent quite a large population of 
urology clinic attenders. A number of medications and treatment modalities 
have been found to be effective for many of these. Nevertheless others fail to 
achieve a satisfactory response and alternatives therefore continue to be 
sought.
3.2 PROPOSED TREATMENT OF STUDY
Botulinum toxin is a highly potent neurotoxin, the therapeutic effects of which 
are principally derived from an alteration in the release of acetylcholine at 
presynaptic junction neurons. Botulinum toxin is approved for treatment of 
muscle over activity associated with several disorders, such as cervical 
dystonias. Clinical trials of its use in cases of detrusor over activity have 
shown encouraging results, both in Europe and America.
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3.3 METHOD CONSIDERATIONS
Historically, urodynamics has been used as the primary outcome measure in 
the assessment of new treatments for the overactive bladder. However, 
scrutiny of the data has demonstrated that this is not the reliable option that 
was assumed. It has been found that urodynamic variables do not relate to 
the severity of a patient’s symptoms, the prognosis nor the outcome of 
treatment174. A recent randomised, double-blind, placebo controlled study of 
tolterodine for detrusor instability has demonstrated urodynamics to play no 
appreciable role in the assessment process175,176.
Nevertheless, it would not be advisable to diagnose patients for this study on 
symptoms alone since this could allow for some doubt as to the true nature of 
the aetiology. It is therefore more appropriate to describe the clinical 
pathology in terms of urodynamics by making the demonstration of detrusor 
instability a recruitment criterion.
It is now well accepted that Quality of Life (QOL) is an important outcome 
measure. The International Continence Society (ICS) has recommended that 
QOL measurements be included in all studies of urinary incontinence as a 
complement to clinical measures. Patients with detrusor over activity have 
QOL scores significantly worse than the general population177'182
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Several QOL measures have been developed, validated and used 
extensively. There are a few specifically for urinary incontinence, including the 
Incontinence Impact Questionnaire, the York Incontinence Perception Scale 
(YIPS), the Incontinence Quality of Life (IQOL), the Incontinence Quality of 
Life index (IQLI) and the King’s Health Questionnaire (KHQ)183'187.
Of them all the KHQ is by far the better validated and has been shown to 
identify a change in response to treatment. On its history of use and 
accumulated experience it presents as the ideal choice from the field188'191.
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3.4 STUDY DESIGN
A matter of significant concern is the nature of the trial limbs. The major multi­
centre clinical trials of oral preparations for treating incontinence have used 
parallel groups. These work well but require large recruitment frames and the 
participation of many centres. Cross-over deigns have been used very 
successfully in contexts similar to those considered in this study. Recent work 
on the use of intra-vesical atropine for the treatment of incontinence in MS, 
funded by the MS Society, has used cross-over methods with great success, 
achieving highly powered studies. There are two reasons for this. The type of 
patients requiring more advanced treatment methods exhibit detrusor 
overactivity that is highly reactive such that the discontinuation of oral 
antimuscarinic agents is associated with a very rapid decline in symptoms. 
This means that carry-over effects that normally prohibit cross-over do not 
feature. Secondly intravesical applications are associated with much greater 
increases in functional bladder capacity than oral preparations. Both atropine 
and oxybutynin have exhibited this property and the current data available on 
botulinum toxin indicates that the same properties feature. This results in a 
very clear discrimination between treatment effect and placebo, or non­
treatment that is not only permissive of a cross-over design but also allows for 
highly powered studies from quite small sample numbers. For example the 
pilot study of intravesical atropine in MS demonstrated a difference in change 
in bladder capacity that was both clinically and statistically significant with a 
sample of 15 patients. Drawing on these experiences we proposed a
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randomised, double-blind, placebo controlled, cross-over design identical to 
that used by Deaney et al in 1998192.
As per the sample size computation 40 patients in each group would give 92% 
power and 30 in each group would give 83% power.
Power as a Function of Sample Size
0.8
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0.4
0.2
0.0
6030 40 5010 20
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3.5 TRIAL OBJECTIVES AND ENDPOINTS 
AIM
To test the hypotheses that the mean difference in change of average voided 
volume, following Botulinum B injection, compared with that following placebo 
is zero.
PRIMARY OUTCOME MEASURE
To compare the changes in the average voided volume in the control and the 
placebo group.
SECONDARY OUTCOME MEASURE
• Frequency
• Incontinence episodes
• Quality of life (Kings Health Questionnaire)
• To compare the differences in change in general quality of life
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3.6 TRIAL DESIGN
A randomized, double-blind, placebo controlled, cross over trial comparing
botulinum toxin B with placebo.
INCLUSION CRITERIA
• Male or female patients aged at least 18 years
• Patients able and willing to attend clinics
• Patients able and willing to complete diary card, including proper
voided volume measurements for at least 48 consecutive hours.
• Patients able to visit toilets without any assistance.
• Patients capable of understanding the research nature of
treatment and the risk of adverse events, and having signed the 
informed consent after full discussion.
• Patients with neurological or non neurological bladder 
instabilities proven by urodynamics.
EXCLUSION CRITERIA
• TCC of the bladder or any other bladder malignancy
• Previous bladder surgery (viz. augmentation cystoplasties)
• Active UTI
Known allergies 
Children
Known prostatic cancer 
Major urethral access problems
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3.7 PRACTICAL METHOD
1. Patients were recruited after having a standard static saline fill 
cystometry with a filling rate of 50ml/minute
2. Patients were handed a voiding diary and a quality of life questionnaire 
at the time of recruitment. These forms are simple to complete. 
Instructions were clear.
3. Patients reported to the day case surgery unit.
4. A urine dipstick was performed to test for leucocyte esterase as 
evidence of infection.
5. A cystoscopy was performed and three biopsies were obtained from 
the dome of the bladder.
6. Each patient was injected with either 5000U of Botulinum toxin B 
(diluted in 20mls. Of saline) or 20mls of placebo, as allocated, 
intravesically. The drugs were prepared by a nurse and both the 
surgeon and the patient were blinded. The test drug was injected in 
equal aliquots over the dome of the bladder, excluding the trigone, at 
10 different sites.
7. Patients went home the same day with a voiding diary and a 
questionnaire. They were prescribed 5 days of Ciprofloxacin 500mg X 
BD to cover for any infections.
8. Patients had a telephonic follow-up after one week to check for any 
side effects.
9. Patients maintained records of frequency, incontinence and voided 
volumes for three days continuously each week.
10. Patients reported to the day case surgery at the end of six weeks, with
the completed voiding diary and a questionnaire, for cystoscopy and 
bladder biopsies. They received the crossover allocation of the study 
drug at this time, injected as previously into the bladder wall at ten 
sites.
11. Patients went home the same day with a new voiding diary and a
questionnaire. They were prescribed five days of Ciproxin 500mg BD 
to cover for any infections.
12. Patients had a telephone follow-up at the end of one week to check for
any side effects.
13. At the end of six weeks, patients were seen in the outpatients’ clinic,
with the completed voiding diary and a questionnaire to assess their 
symptoms and progress.
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Week 1
Dayl
Date
Day2
Date
Day3
Date
Day Day Day _
toilet
(ml)
catheter
(ml)
wet toilet
(ml)
catheter
(ml)
wet toilet
(ml)
catheter
(ml)
wet
6-7am
7-8am
8-9am
9 -10am
10-1 lam
11-12am
12-lpm
l-2pm
2-3pm
3-4pm
4-5pm
5-6pm
6-7pm
7-8pm
8-9pm
9 -10pm
10-11pm
1 l-12pm
12-lam
l-2am
2-3am
3-4am
4-5am
5-6am
Totals L L I
Figure 3.1 
Voiding Diary
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Bladder symptom questionnaire
Name............................................................................................
Date o f b irth ................................................................................
Sex F / M ................................................................................
Hospital number.........................................................................
N o n e  S om e M u c h
© © ©
Do you experience urgency? That is having
to hurry in order to pass urine ? ©  ©  ©  1
Do you experience urge incontinence? That 
is hurrying to pass urine and not making
it in time? ©  ©  ©  2
Does cold weather make your bladder
symptoms worse? ©  ©  ©  3
Do you find that running water from 
a tap causes urinary urgency or
incontinence? ©  ©  ©  4
Do you find that putting a key in the 
front door when returning home 
causes urinary urgency or
incontinence? ©  ©  ©  5
Do you find that on getting up from 
bed in the morning you experience
urgency or urge incontinence ? ©  ©  ©  6
Is there any pain associated with
the urgency ? ©  ©  ©  7
Do you ever leak urine on: 
coughing, sneezing, running.
laughing, lifting? ©  ©  ©  8
D a te
Figure 3.2
Urgency symptom 
questionnaire
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Kings Health Q uestionnaire
Present Health Tick One
Very Good
Good
Fair
Poor
Very Poor
Affect on Life Tick one
Not at all
A little
Moderately
A Lot
A Little Moderately A Lot
Frequency
Nocturia
Urgency
Urge Incontinence
Stress Incontinence
Nocturnal Enuresis
Intercourse Incontinence
Frequent UTI
Bladder Pain
Difficult Micturition
Not at all Slightly Moderately A Lot
Role Limitations (Impact on)
Household tasks
External tasks
Physical and social Limitations 
(Impact on)
Physical activities
T ravel
Social Life
Visiting Friends
Personal Relationships (Impact 
On)
Relationship with partner
Sex Life
Family life
Emotions
Depression
Anxious or Nervous
Impact on self esteem
Sleep or energy
impact on sleep
Tiredness
Never Som etim es Often All the times
W ear Pads
Watchful fluid intake
Change underclothes
W orry in case you smell
Embarrassment
Figure 3.3
King’s Health questionnaire
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3.8 PRACTICAL PROCEDURES AFFECTING THE PATIENT
3.8.1 THE URODYNAMIC METHOD
Patients were asked to empty their bladders.
A Nelaton Jacques catheter (French gauge 10) and a nylon epidural catheter 
916g) were introduced into the bladder via the urethra, which had been 
anaesthetised by 2% lignocaine gel.
The post micturition residual urine was drained off and its volume measured.
Another P.V.C catheter (French gauge 10) tipped with perforated latex sheath, 
to avoid faecal plugging, was introduced into the rectum.
The small bladder catheter and rectal catheter were filled with normal saline 
and then connected to force displacement transducers mounted at the level of 
the superior ramus of the pubic bone. This reference point was used to 
calibrate the transducers to atmospheric pressure.
The intrinsic detrusor pressure generated by the walls of the bladder, was 
calculated by subtracting the intra abdominal pressure (measured via the 
rectal catheter) from the bladder pressure (measured via the epidural 
catheter).
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The bladder was filled with normal saline at 20°C at a rate of 1ml sec'1. The 
analogue data obtained from the transducers were digitised and collected by 
micro-computer and stored on magnetic disk at a rate of 6 cycles sec'1.
The bladder was filled until either a maximum of 500ml had been infused; or 
detrusor overactivity prohibited further filling; or the patient was found to be 
unable to tolerate further infusion.
On completion of the filling study the Nelaton Jacques catheter was withdrawn 
from the bladder and the patient was then asked to void to completion.
The digitised data was analysed so as to calculate the study variables.
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Figure 3.4 
The Urodynamics equipment.
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3.8.2 CYSTOSCOPY AND BLADDER BIOPSIES UNDER SEDO- 
ANALGESIA
This procedure was performed routinely in many urological patients in the day 
case surgery unit. It involved a look inside the bladder using a Millerscope 
(size17) under cover of mild sedation using intravenous midazolam. This has 
been termed as sedoanalgesia in the past193'197.
Midazolam was used to produce sleepiness or drowsiness and to relieve 
anxiety before surgery or certain procedures. It was also used to produce 
sleep before and during surgery. Midazolam was used sometimes in patients 
in intensive care units in hospitals to cause sleep. This allowed the patients to 
withstand the stress of being in the intensive care unit. Midazolam was given 
only by or under the immediate supervision of a doctor trained to use this 
medicine.
The dose of midazolam was be different for different patients. The dose 
depending on:
• Age;
• Weight;
• General physical condition;
• The kind of procedure
• Other medicines the patient is taking or will receive before and during 
the procedure
Along with its needed effects, a medicine may cause some unwanted effects. 
While patients were receiving midazolam the doctor monitored closely for the 
side effects. The following is a complete list of side effects of midazolam:
Fluctuations in respiratory rate, including decreased respiratory rate and tidal 
volume, apnoea, variations in blood pressure and pulse rate are common. The 
following are general side effects regardless of the route of administration.
Cardiovascular: Hypotension, cardiac arrest.
Nervous system: Oversedation, headache, drowsiness, grogginess, 
confusion, retrograde amnesia, euphoria, nervousness, agitation, anxiety, 
argumentativeness, restlessness, emergence delirium, increased time for 
emergence, dreaming during emergence, nightmares, insomnia, tonic-clonic 
movements, ataxia, muscle tremor, involuntary or athetoid movements, 
dizziness, dysphoria, dysphonia, slurred speech, paresthesia.
Gastorinestinal: Hiccoughs, N&V, acid taste, retching, excessive salivation.
Ophthalmologic: Double vision, blurred vision, nystagmus, pinpoint pupils, 
visual disturbances, cyclic eyelid movements, difficulty in focusing.
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Dermatologic: Hives, swelling or feeling of burning, warmth or cold feeling at 
injection site, hive-like wheal at injection site, pruritus, rash.
Miscellaneous: Blocked ears, loss of balance, chills, weakness, faint feeling, 
lethargy, yawning, toothache, and haematoma.
Some side effects may occur but it is very usual that they do not need medical 
attention. Most side effects will go away as the effects of midazolam wear off. 
The patients could therefore be discharged from the hospital the same day.
Biopsy specimens, which included detrusor muscle, were prepared for 
histopathological examination after fixation and H & E staining.
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Figure 3.5 
The Millerscope and the 
semirigid Needle
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Figure 3.6 
The Needle piercing the 
detrusor
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3.9 STATISTICAL METHODS
3.9.1 POWER FOR A TEST OF THE NULL HYPOTHESIS
One goal of the proposed study was to test the null hypothesis that the mean 
difference (or change) within pairs was 0.00. The criterion for significance 
(alpha) was set at 0.05. The test was 2-tailed, which means that an effect in 
the either direction would be interpreted.
With the proposed sample size of 20 pairs of cases, the study had power of 
86.3% to yield a statistically significant result.
The computation assumed that the population from which the sample was 
drawn exhibited a mean difference in average voided volume of 90 ml with a 
standard deviation of 125.0. The observed value was to be tested against a 
theoretical value (constant) of 0.00.
This effect was selected as the smallest effect that could be important to 
detect, in the sense that any smaller effect could not be of clinical or 
substantive significance. Rather than make an arbitrary judgement or guess at 
a suitable effect size we used the value of 90 ml (sd=125 ml) which had been 
found in a study of intravesical atropine. This study, which was conducted on 
patients with MS had found this difference in association with a marked
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change for the better in the quality of life of the participating patients. We had 
evidence therefore that this change was of clinical significance.
We also assumed that this effect size was reasonable, in the sense that an 
effect of this magnitude could be anticipated in this field of research. On this 
point we assumed some similarity between responses to intravesical atropine 
and the intra-detrusor injection of botulinum toxin.
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3.9.2 PRECISION FOR ESTIMATING THE EFFECT SIZE
A second goal of this study was to estimate the mean difference in the 
population. On average a study of this design would enable us to report the 
mean difference with a precision (95.0% confidence level) of +/- 57.47 points. 
For example, an observed mean difference of 90.0 would be reported with a 
95.0% confidence interval of 32.53 to 147.47.
The precision estimated here is the median precision. Precision will vary as a 
function of the observed standard deviation (as well as sample size), and in 
any single study would be expected to be narrower or wider than this 
estimate.
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Chapter 4 RESULTS 
4.1 RECRUITMENT
Between April 2003 and August 2004, 30 patients were identified as eligible 
for the trial because of their symptoms.
Two were unwilling to participate. Eight patients did not show unstable 
contractions on urodynamics so they were not included in the study.
20 patients, 3 males and 17 females with a mean age of 50 (SD=16) entered 
the trial.
Of these, 3 female patients had neurogenic and 17 had non neurogenic 
detrusor overactivity.
No patient showed evidence of low compliance.
4.2 TRIAL PROFILE
10 patients received 5000IU of BTX B followed by the placebo six weeks later 
and the other 10 received placebo followed by 5000IU of BTX B (Figure 3.1).
8 patients unsuitable after 
urodynamics
10 qualified for analysis 10 qualified for analysis
2 Patients unwilling to 
participate
30 patients eligible on the 
basis of their symptoms
2 patients did not 
complete the trial 
(Urinary 
retention)
20 patients with refractory 
detrusor activity recruited 
and randomised
10 patients completed the 
study
8 patients completed the 
study
10 patients received 5000U  
BTX B and then placebo (after 
6 weeks washout) phase 1
10 patients received placebo 
and then 5000U BTX B (after 6 
weeks washout) phase 2
Figure 4.1 
Trial Profile
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4.3 RANDOMISATION AND BLINDING
All the patients were recruited by the lead researcher. A computerised random 
number generator was used by the clinical trials pharmacist, to draw up a 
randomisation schedule for treatment allocation. Identical packages were 
produced containing the trial medication (active/placebo) according to the 
randomisation schedule. The contents of these were known only to the clinical 
trials pharmacist. The syringes of the trial medication were prepared by the 
unblinded nurse, who was specifically assigned this task and had no other 
involvement with the trial or the patients.
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4.4 ANALYSIS 
INTENTION TO TREAT
Two patients, who developed retention, provided absent data fields. Their 
most recent datasets were collected at baseline and these were copied into 
the gaps left in the spreadsheet.
SUBSET ANALYSIS (PER PROTOCOL)
A subset analysis on the basis of per protocol data was also effected where 
the data from the patients, who did not complete the trial, was excluded.
In addition to this another subset was identified. This was of the patients who 
did not have neurogenic detrusor overactivity (“Idiopathic detrusor 
overactivity”). These were 17 in number. An independent analysis was carried 
out for this subset.
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Placebo Phase
End fP phase)
Treatm ent Phase
End (D phase)
Between Group Difference in A 
A D - A P = True Drug Effect
Figure 4.2 
Result Analysis
Placebo Phase  
Run-in (R 0)
Treatm ent Phase 
Run-in (R 0)
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4.5 PRIMARY OUTCOME MEASURE- AVERAGE VOIDED VOLUME
The Wilcoxon Signed Ranks Test was used to test the paired difference in 
change between treatment phases. Little carry-over was noted in the second 
arm placebo and the placebo data from both arms were included in the 
analysis.
Paired differences, between treatment arms, in the changes from baseline 
were found for the primary outcome variable, average voided volume.
The median difference and the confidence intervals were sought:
Wilcoxon Signed Ranks Test Statistic Z = -2.5; p= 0.012; Median difference in 
change = + 65 ml 95% C.l. = +11, +121
The results are illustrated in Table 3.1. Figure 3.2 illustrates the median and 
95% C.l. for the primary outcome measure during run-in, and the two 
treatment arms. The paired difference between active treatment and the other 
two phases is evident.
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Median 95% Confidence 
intervals
Lower Upper
Baseline 126.7 92.1 171.1
Active 228.6 162.6 279.5
Placebo 151.4 98.9 187.2
Change from baseline 
on active treatment
83.0 6.1 132.4
Change from baseline 
on placebo
4.48 -4.05 43.43
Wilcoxon Signed Ranks Test Statistic Z = -2.5; p= 0. 
change = + 65 ml 95% C.l. = +11, +121
012; Median c ifference in
Table 4.1
Median of absolute values and their change
for average voided volume
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Figure 2
Average Voided Volume by Treatment Group
30 0
200
100
0
Active Baseline Placebo
Treatment Group
Median and 95% Cl
Upper 
Lower 
□  M edian
Figure 4.3
The median and 95% C.l. for the primary 
outcome measure during run-in, and the 
two treatment arms
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4.6 SECONDARY OUTCOME MEASURES 
WEEKLY FREQUENCY
The Wilcoxon Signed Ranks Test was used to test the paired difference in 
change between treatment phases. Little carry-over was noted in the second 
arm placebo and the placebo data from both arms were included in the 
analysis.
Paired differences, between treatment arms, in the changes from baseline 
were found for weekly frequency.
Wilcoxon Signed Ranks Test Statistic Z = -2.1; p= 0.033; Median difference in 
change = -9 / week 95% C.l. = -19.5, -0.5
The results are illustrated in Table 3.2. Figure 3.3 illustrates the median and 
95% C.l. for the primary outcome measure during run-in, and the two 
treatment arms. The paired difference between active treatment and the other 
two phases is evident.
Median 95% Confidence 
intervals
Lower Upper
Baseline 67.50 54.47 78.00
Active 40.00 36.24 48.00
Placebo 55.00 44.47 65.29
Change from baseline 
on active treatment
-22.5 -32.76 -10.41
Change from baseline 
on placebo
-14.00 -20.29 -5.23
Wilcoxon Signed Ranks Test Statistic Z = -2.1; p= 0. 
change = -9 / week 95% C.l. = -19.5, -0.5
033; Median <j ifference in
Table 4.2
Median of absolute values and their change
for weekly frequency
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Figure 3
Weekly frequency by treatment group
Median and 95% Cl
Upper 
Lower 
□  M edian
Active Baseline Placebo
Treatment Group
Figure 4.4
The median and 95% C.l. for the weekly 
frequency during run-in, and the two 
treatment arms
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WEEKLY INCONTINENCE
The Wilcoxon Signed Ranks Test was used to test the paired difference in 
change between treatment phases. Little carry-over was noted in the second 
arm placebo and the placebo data from both arms were included in the 
analysis.
Paired differences, between treatment arms, in the changes from baseline 
were found for weekly frequency.
Wilcoxon Signed Ranks Test Statistic Z = -2.1; p= 0.033; Median difference in 
change = -9 / week 95% C.l. = -19.5, -0.5
The results are illustrated in Table 3.2. Figure 3.3 illustrates the median and 
95% C.l. for the primary outcome measure during run-in, and the two 
treatment arms. The paired difference between active treatment and the other 
two phases is evident.
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Median 95% Confidence 
intervals
Lower Upper
Baseline 19.00 12.00 41.94
Active 1.50 0.00 2.76
Placebo 12.00 8.47 24.82
Change from baseline 
on active treatment
-17.00 -40.41 -7.70
Change from baseline 
on placebo
-8.50 -16.53 -2.00
Wilcoxon Signed Ranks Test Statistic Z = -3.3; p= 0. 
change = -12 / week 95% C.l. = -24, -5.
001; Median difference in
Table 4.3
Median of absolute values and their change
for weekly incontinence
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Figure 4
Weekly incontinence episodes by treatment group
50
4 0 -
3 0 -
2 0 -
Median and 95% Cl1 0 -
Upper
Lower
M edian-10
Active Baseline Placebo
Treatment Group
Figure 4.5
The median and 95% C.l. for the weekly 
incontinence during run-in, and the two 
treatment arms
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QUALITY OF LIFE (KINGS HEALTH QUESTIONNAIRE (KHQ))
Nowadays measures of Quality of Life (QOL) are considered to be important 
additional outcome measures, essential in clinical trials. The International 
Continence Society (ICS) has recommended that QOL measurements be 
included in all studies of urinary incontinence as a complement to clinical 
measures. Patients with detrusor over activity have QOL scores significantly 
worse than the general population.
The Wilcoxon Signed Ranks Test was used to test the paired difference in 
change between treatment phases. Little carry-over was noted in the second 
arm placebo and the placebo data from both arms were included in the 
analysis.
There were also significant paired differences, between treatment arms, in the 
change, from baseline, in a number of domains of the KHQ measure of QOL.
Specifically, it was found that active treatment was associated with clinically 
significant improvements in the impact of the disease on the patient’s life, the 
impact on incontinence, physical and social limitations, sleep/energy 
disturbance and incontinence severity measure i.e. domains 1, 2, 3, 5, 8 and 
9.
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Domain Median
95%
Confidence
interval
Test
Statistic
Z
P
Lower Upper
Domain 1 Active 1.00 1.00 1.50
(Present Placebo 1.50 1.00 2.00 -0.82 0.4
health) Baseline 2.00 1.00 2.00
Domain 2 Active 1.50 1.00 2.00
(Impact on life) Placebo 2.50 2.00 3.00 -2.9 0.004Baseline 3.00 2.50 3.00
Domain 3 Active 4.50 2.50 6.50
(Incontinence Placebo 7.00 5.00 9.50 -2.2 0.03
impact) Baseline 9.00 7.50 11.00
Domain 4 Active 2.50 1.00 3.50
(Role Placebo 3.50 2.50 4.50 -1.8 0.07
limitations) Baseline 4.00 3.00 4.50
Domain 5 Active 5.00 3.00 6.50
(Physical/Social Placebo 7.50 5.50 10.00 -2.2 0.03limitations) Baseline 9.00 7.50 10.50
Domain 6 Active 2.00 1.00 4.50
(Personal Placebo 3.50 1.50 5.50 -1.0 0.3
relationships) Baseline 4.50 3.00 6.50
Domain 7 Active 5.25 3.00 6.50
(Emotional Placebo 7.00 5.00 8.50 -1.6 0.11problems) Baseline 7.50 6.50 9.00
Domain 8 Active 3.50 2.00 4.50
(Sleep/Energy Placebo 5.00 3.50 5.50 -2.0 0.04disturbances) Baseline 5.00 4.50 6.00
Domain 9 Active 8.50 5.50 10.50
(Incontinence Placebo 12.00 9.50 14.50 -2.4 0.02severity
measures)
Baseline 12.00 10.00 14.00
Table 4.4 
Domains covered by the King’s Health 
Questionnaire. - Median of raw scores with 
95% Cl and the Wilcoxon Signed Ranks Test 
statistics
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Chapters SIDE EFFECTS
5.1 BACKGROUND
Botulinum toxin has long been infamous for causing botulism. Some of its 
earliest and still some of its best clinical descriptions highlight not only paresis 
but also autonomic dysfunction, especially accommodation problems, reduced 
sweating, high skin temperature and reduced cerumen production as 
botulism’s cardinal features.
When intramuscular injections were first used to reduce muscular 
hyperactivity disorders, their effect was strictly local, and no autonomic 
dysfunction was observed. It was believed that lack of systemic spread was 
due to a specific and robust BTX-A binding to glycoprotein ‘acceptors’.
Later, with the use of higher doses of BTX-A, jitter examinations revealed 
some systemic motor side effects, residual urine volumes and heart rate 
variabilities, suggesting some autonomic dysfunction. None of these findings 
were, however, noticed by the patient nor were they clinically relevant.
There have been quite a few reports of successful usage of BTX A in cases of 
detrusor overactivity.
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None of these studies suggest any adverse effects from these injections 
apart from a mention of generalised muscle weakness in a couple of patients 
as a side effect of this treatment198
The known side effects of Botulinum toxin: Nausea, vomiting, dry mouth, 
dysphagia, weakness of the respiratory muscles and paresis have not. 199
The use of BT-B has been reported to treat successfully a patient with 
detrusor hyperreflexia secondary to multiple sclerosis. This was followed by 
an open-label dose-escalation study using BT-B to determine its preliminary 
efficacy and safety in 15 patients with overactive bladder. No serious side 
effects were reported, apart from dry mouth in two patients. The dose range 
used was 2500 IU to 15,000 III.111
There was a recent open controlled study involving 30 consecutive patients in 
which 24 were treated for Cervical dystonia (11,310 U +/- 2,616U of BTX-B) 
and 6 were treated for focal Hyperhidrosis (4,000-10,000 U). In 5 of them 
BTX-A was used additionally for comparison of effectiveness.
In CD, side effects consisted of dryness of mouth (21), accommodation 
difficulties (7), conjunctival irritation (5), reduced sweating (4), swallowing 
difficulties (3), heartburn (3), constipation (3), bladder voiding difficulties (2), 
head instability (1), dryness of nasal mucosa (1) and thrush (1).ln 
Hyperhidrosis, side effects consisted of dryness of mouth (2), 
accommodation difficulties (4) and conjunctival irritation (1). It was concluded
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that autonomic side effects occurred far more often with BTX-B than BTX-A. 
Their localisation suggested systemic spread.198
BTX-B should be applied carefully in patients with autonomic dysfunction, 
additional anticholinergic treatment and in conditions where anticholinergics 
are contraindicated.
5.2 SIDE EFFECT PROFILE IN THE CURRENT STUDY
In the current study, a 79-year old man went into urinary retention, as did a 
74-year old lady. The urinary retention resolved after six weeks of intermittent 
self-catheterisation. The man also described constipation, as did a 28-year old 
woman who additionally experienced a dry mouth. A 62-year old lady noted a 
dry mouth and general malaise. These side effects, in four patients were self- 
limiting.
The fact that four of our twenty patients also observed varying side effects 
including acute urinary retention (2), dry mouth (3), constipation (2) and ‘flu­
like syndrome’ (1) after intravesical injection of 5000 IU of BT-B raises a 
suspicion that BT-B does seem to have a high affinity for autonomic nerve 
endings.
The critical dose at which it seems to attack them cannot be decided yet. This 
is because studies utilising up to 15000 IU have reported little or no side 
effects while in our study adverse effects were noted at a dose as low as 
5000IU.
Currently, there is no standard method for identifying adverse events that 
occur during a clinical trial. The implications of this lack of consistent 
ascertainment methods are substantial as comparisons of rates of reported
side effects from 2 or more drugs may not be valid if the methods of collecting 
adverse events differ. This could impair the ability of patients and physicians 
to compare the risk- benefit profile of drugs.
Several previous studies have compared the use of open-ended questions 
and checklists to determine the frequency of reported adverse events in a 
clinical trial. All of these studies assigned patients to receive both methods of 
adverse event collection, with the open-ended question being administered 
first; no randomized comparisons were performed. This method has the 
potential to bias the participants’ response to the checklist because they are 
initially “primed” by the open-ended question200,201.
In a randomized, controlled trial, it was found that a checklist method of 
identifying adverse events dramatically increased the number of reported 
events compared with open-ended questions. Although this finding is intuitive, 
the magnitude of effect has important implications both for the conduct of 
clinical trials and for assessment of the risk- benefit profile of drugs and other
PO Pinterventions .
Since it is common practice for physicians and patients to select drugs and 
other interventions on the basis of their reported rate of side effects, if different 
drugs used for the same indication are examined in clinical trials that use 
different methods of identifying adverse events, then it is not valid to compare 
the reported rate of side effects.
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One could make rational arguments for using a checklist, an open-ended 
question, or other techniques to identify adverse events in clinical trials. 
However, use of different methods for collecting data in different clinical trials 
limits the ability to compare the side effect profile of drugs. The use of the 
CONSORT (Consolidated Standards of Reporting Trials) statement has 
helped to make clinical trials more uniform and comparable203.
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Chapter 6 HISTOLOGY
6.1 INTRODUCTION AND BACKGROUND
Botulinum toxin selectively blocks the release of acetylcholine from nerve 
endings by inhibiting the exocytosis of presynaptic acetylcholine vesicles. 
Ultrastructural studies of the neurogenic overactive detrusor due to spinal cord 
injury, meningomyelocele and brain disorders, that have been treated with 
botulinum toxin type A, have demonstrated changes in the intrinsic innervation 
including a widespread axonal degeneration and a limited axonal 
regeneration combined with schwann cell activation independent of the 
duration of the neurogenic disorder204.
Myogenic changes included the presence of different extents of muscle 
degeneration, a reduction of intermediate cell junctions of muscle cells and a 
dominance of intimate cell appositions with much narrower junctional gaps 
forming chains >= 5 muscle cells205'207
Local changes (viz. inflammation, fibrosis, necrosis etc.) after the injection of 
Botulinum toxin B into the overactive detrusor, however, have not been looked 
at, till date. This is apposite because the agent is an imunogenic peptide that 
is known to induce an antibody response. If this treatment were to induce a 
local acute or chronic inflammatory reaction, it would be a very significant 
matter.
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6.2 METHODS
20 patients with refractory detrusor overactivity were recruited for this 
randomised, double bind, placebo controlled, cross over trial.
An attempt was made to obtain bladder biopsies from all the patients on each 
of their visits to the day surgery unit.
Since the procedure was done under sedo analgesia, not all the attempts to 
biopsy the bladder were successful. Some of the patients found the cold cup 
biopsies quite uncomfortable and the procedure had to be abandoned in 
these cases.
In all 26 biopsies were obtained from 20 patients and were divided into three 
groups:
Group I: Biopsies obtained from the normal detrusor (before any injection) 
Group II: Biopsies after 6 weeks of intradetrusor injection of placebo (Normal 
saline)
Group III: Biopsies after 6 weeks of intradetrusor injection of botulinum toxin B
There numbers were as follows:
Group I: 13 
Group II: 8 
Group III: 5
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These biopsies were prepared using the standard methods of fixation, 
mounting and staining with Haematoxylin and Eosin (H & E). The resulting 
slides were then evaluated for local changes by two examiners (Maneesh 
Ghei and Dr Debbie Hopster) both blinded to the clinical / urodynamic data.
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6.3 PRACTICAL PROCEDURES 
TISSUE PROCESSING
Once the tissue was fixed in formalin, it was processed into into thin 
microscopic sections. The tissues embedded in paraffin wax, which is similar 
in density to tissue. The blocks thus prepared were sectioned using a 
microtome into slithers of 6-8 microns in depth.
The main steps in this process were dehydration and clearing.
Wet fixed tissues (in aqueous solutions) cannot be directly infiltrated with 
paraffin. First, the water from the tissues was removed by dehydration. This 
was usually done with a series of alcohols, 70% to 100%. Other dehydrants 
can be used, but have major disadvantages.
The next step was "clearing" and consisted of removing the dehydrant with a 
substance that was miscible with the embedding medium (paraffin). Xylene 
was used for this purpose.
Finally, the tissues were infiltrated with the embedding agent, paraffin.
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This "embedding" process is very important, because the tissues must be 
aligned, or oriented, properly in the block of paraffin.
Once the tissues were embedded, they were cut into sections that could be 
placed on a slide. This was done with a microtome. The microtome is nothing 
more than a knife with a mechanism for advancing a paraffin block standard 
distances across it.
Once sections were cut, they were floated on a warm water bath that helped 
remove wrinkles. Then they were picked up on a glass microscopic slide. The 
embedding process was reversed in order to get the paraffin wax out of the 
tissue and allow water soluble dyes to penetrate the sections. Therefore, 
before any staining was done, the slides were "deparaffinized" by running 
them through xylenes (or substitutes) to alcohols to water. This was done 
since there are no stains that can be used on tissues containing paraffin.
H and E staining
This is the most routinely used method of staining. All the other stains are 
called special stains.
Haematoxylin is the oxidized product of the logwood tree known as haematin. 
Since this tree is very rare nowadays, most haematin is of the synthetic 
variety. In order to use it as a stain it must be "ripened" or oxidized. This can 
be done naturally by putting the haematin solution on the shelf and waiting 
several months, or by buying commercially ripened haematoxylin or by putting 
ripening agents in the haematin solution.
Haematoxylin will not directly stain tissues, but needs a "mordant" or link to 
the tissues. This is provided by a metal cation such as iron, aluminium, or 
tungsten. The variety of haematoxylins available for use is based partially on 
choice of metal ion used. They vary in intensity or hue. Haematoxylin, being a 
basic dye, has an affinity for the nucleic acids of the cell nucleus.
Haematoxylin stains are either "regressive" or "progressive". With a 
regressive stain, the slides are left in the solution for a set period of time and 
then taken back through a solution such as acid-alcohol that removes part of 
the stain. This method works best for large batches of slides to be stained and
is more predictable on a day to day basis. With a progressive stain the slide is 
dipped in the haematoxylin until the desired intensity of staining is achieved, 
such as with a frozen section. This is simple for a single slide, but lends itself 
poorly to batch processing.
Eosin is an acidic dye with an affinity for cytoplasmic components of the cell. 
There are a variety of eosins that can be synthesized for use, varying in their 
hue, but they all work about the same. Eosin is much more forgiving than 
haematoxylin and is less of a problem in the lab. About the only problem one 
sees is overstaining, especially with decalcified tissues.
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6.4 RESULTS
Of the 26 biopsies obtained, one was inadequate and one of the pots did not 
contain a specimen.
Hence 24 biopsies were examined by two examiners, one a pathologist, who 
were blinded to the clinical data.
Not all the biopsies included muscularis propria. Their content has been 
described in table 5.1
The mounted preparations were scrutinised for the following changes:
• Acute inflammation
• Chronic inflammation
• Fibrosis
• Necrosis and
• Vascularity
A mixture of all these patterns was observed in all the biopsies and this has 
been tabulated in table 6.2 and figs 6.1-6.5.
No pattern dominated the picture significantly in any of the biopsies.
It would be wrong to propose that the chronic inflammation observed in these 
biopsies was a result of the injections since it was seen in the pre injection 
biopsies as well. It may be that these findings suggest that cystitis is 
associated with overactive bladder.
It has been suggested that the link between inflammation and the Painful 
Bladder Syndrome / Interstitial Cystitis symptoms of frequency, urgency, and
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pain may lie in the bladder’s neuroplastic response to inflammation. 
Irrespective of the type of inflammatory stimulus present, the bladder has 
been shown to respond with an increase in cytokine production (mainly Nerve 
growth factor (NGF) production, as well as with morphologic changes in 
sensory neurons that innervate the bladder.
Basic science studies have shown that various insults to the bladder (eg, 
mechanical, chemical, immune) lead to increased NGF production and 
morphologic changes (ie, neuroplasticity) in sensory and motor neurons. 
Different insults, including a bladder infection, theoretically could result in a 
common neuroinflammatory response that potentially could lead to persistent 
symptoms, even when the initial inflammatory stimulus subsides208.
Further support of the role of inflammation in overactive bladder and PBS/IC 
was demonstrated by Jang et al. In a rodent model of overactive bladder, they 
demonstrated that intravesical instillation of nonsteroidal anti-inflammatory 
drugs can alter the expression of inflammatory modulators and cytokines in 
bladder tissue. Cyclooxygenase- 2 inhibitors reduced the expression of 
inducible nitric oxide synthase and NGF in treated rats. The effect was also 
seen as improvements in parameters of detrusor contraction when compared 
with rats with untreated overactive bladder209.
Furthermore, Saito et al. tested the use of the anti-inflammatory drug 
loxoprofen on lower urinary tract symptoms in men and women with BPH
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and/or overactive bladder. Specifically, there was a reduction of nocturia in 
these patients after 1 week of treatment210.
In an experimental model of cystitis, Gonzalez et al. found that 
lipopolysaccharide from the bacteria Escherichia co//caused an increase in 
NGF and substance P. In addition, treatment with RDP58, a synthetic peptide 
that inhibits early signal transduction pathways for the expression of 
inflammatory cytokines, decreased NGF and substance P production along 
with histopathologic inflammation. Therefore, by decreasing the production of 
inflammatory and neurotrophic factors, RDP58 modulates the neuroplastic 
response to inflammation and may play a role in treating inflammatory bladder 
disorders211.
Thus the complex association between inflammatory cells, cytokines, and the 
nervous system may be responsible for the pathogenesis and progression of 
overactive bladder, and PBS/IC symptoms. Inflammatory cells and their 
cytokines, found in tissue or in secretions, may act as an extension of the 
peripheral nervous system in the bladder’s immunosensory loop, mediating 
the symptoms of all these syndromes.
One of the specimens examined post-botulinum toxin B (6 weeks after the 
injection) did show necrosis in the muscularis propria. There were no grounds 
for judging whether this resulted from the injection or it was a process of the 
overactive bladder.
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This phenomenon was not observed in any of the other biopsies obtained 
post-botulinum toxin B injections.
The histology results from our study concur with the general experience that 
Botulinum toxin does not cause fibrosis of the muscles local to the site of 
injection when it is used for other indications. The number of biopsies in the 
present study was small and we studied the effect of the injections after six 
weeks only.
We do not know whether the smooth muscles will react differently when 
repeated injections are used and at a higher dosage. Studies with larger 
numbers and longer follow ups would be required to ascertain definitively, 
whether fibrosis or other derogatory changes occur to the smooth muscle after 
Botulinum toxin injections.
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BIOPSY EPITHELIUM MUSCULARIS
MUCOSA
MUSCULARIS
PROPRIA
A +, D.N +, N -
B +,D + +,N
C +» N - -
D +. N - +
E +, D,N + -
F +, N + -
G +, D.N + -
H +» N + -
I +,D - +
J +, D.N + -
K* +,N - -
L +,N - -
M +, N + +
N D + -
O +, D,N + -
P + + +
Q + + -
R + - +
S +, D, N + +
T + + -
U +, D,N + -
V +,D - -
w**
X + - +
Y +, D, N - -
z + - +
D: DenudedN: Normal*: Suboptimal**: No specimen
Table 6.1 
Biopsies containing 
epithelium, lamina propria 
and muscularis propria
SPECIAL NOTE
THIS ITEM IS BOUND IN SUCH A 
MANNER AND WHILE EVERY 
EFFORT HAS BEEN MADE TO 
REPRODUCE THE CENTRES, FORCE 
WOULD RESULT IN DAMAGE
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BIOPSY ACUTE
INFLAMMATION
CHRONIC
INFLAMMATION
FIBROSIS VASCULARITY NECROSIS
A - + - P -
B - + - NP -
C - + - NP -
D - + - NP +
E - + - P -
F - + - P -
G - + - P -
H - + - P -
1 - + - P -
J - + - P -
K SUBOPTIMAL SPECIMEN
L - + - P -
M - + ++ P -
N - + - NP -
O - ++ - P -
P - + + P -
Q + +++ - P -
R - +++ - P -
S - + - P -
T - + - P -
U - ++ - P -
V - + - NP -
w NO SPECIMEN
X - + ++ P -
Y - + - NP -
z - + + P -
P: Prominent NP: Not prominent
Table 6.2 
Biopsies with evidence of 
acute and chronic 
inflammation, fibrosis and 
necrosis
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CODE BIOPSY TYPE
A NORMAL
B POST NORMAL SALINE
C NORMAL
D POST BOTULINUM TOXIN B
E NORMAL
F POST NORMAL SALINE
G NORMAL
H POST BOTULINUM TOXIN B
1 NORMAL
J POST NORMAL SALINE
K NORMAL
L POST NORMAL SALINE
M POST NORMAL SALINE
N POST BOTULINUM TOXIN B
0 NORMAL
P POST NORMAL SALINE
Q NORMAL
R POST BOTULINUM TOXIN B
S NORMAL
T POST NORMAL SALINE
U POST NORMAL SALINE
V NORMAL
w NORMAL
X NORMAL
Y NORMAL
z POST BOTULINUM TOXIN B
Table 6.3 
Key for Biopsy codes
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Figure 6.1
Normal Detrusor
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Figure 6.2 
Detrusor showing 
aggregates of neutrophils 
in Acute inflammation
Figure 6.3 
Detrusor showing 
aggregates of lymphocytes 
(lymphoid follicle) in 
Chronic inflammation
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Figure 6.4
Detrusor with fibrosis
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Figure 6.5
Detrusor with necrosis
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Chapter 7 DISCUSSION
7.1 PRESENT STUDY
This randomised double-blind, placebo controlled crossover study has 
furnished evidence in favour of the efficacy of Botulinum Toxin B in the 
treatment of recalcitrant overactive bladder symptoms. The study was 
properly powered and the evidence from the primary outcome measure was 
reflected by the secondary measures including those assessing Quality of 
Life.
The experiment illustrates the utility of a cross-over design. This has not been 
favoured for studies of urinary incontinence because of speculative beliefs 
about the influence of carry-over effects confounding the treatment response. 
Unlike an oral medication, with a short half-life, BTX-B showed measurable 
effects up to six weeks and there is evidence of a carry-over into the placebo 
arm. Nevertheless, this did not prohibit a between phase analysis using all of 
the placebo data. As this study illustrates, the design permits a much smaller 
sample size with the associated reduction in costs and logistical difficulties. 
Fewer patients are inconvenienced and the important efficacy data can be 
provided in a much shorter time.
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The data were analysed on an intention-to-treat basis. Two patients withdrew 
after receiving active drug. The non-parametric methods used in the analysis 
should minimise the effect of their data.
This center bought the test drug independently on the open market. The 
placebo and active components were prepared by the hospital pharmacy. The 
study was effected independently of the manufacturer 212.This took place 
before the European Clinical Trials Directive 2001/20/EC came into effect on 
1st May 2004, whilst it is still possible to accomplish such a study, now it 
would be more difficult and expensive. The host Trust would have to agree to 
“Sponsor Status” and the indemnity costs associated with that could be high.
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7.2 LIMITATIONS AND CRITICISMS OF THE STUDY
Possible error could have been introduced through underestimate of carry­
over effect but this would have reduced apparent efficacy. The dose of drug 
was based on a pilot study by Dykstra DD (2003) on 15 patients which used 
dose escalation. It may be that the dose of 5,000 IU was not optimal. 
Enquiries were made about side effects without leading questions so these 
may have been underestimated.
This treatment was not without side effects. Urinary retention, requiring 
intermittent catheterisation was a theoretical risk, about which all patients 
were warned. The data from this experiment mean that is very important that 
patients understand when making judgments on the balance of gain. 
Antimuscarinic side-effects, excluding urinary retention, have been noted 
when BTX has been used to treat dystonias 1" .
This study of 5,000 IU of BTX-B shows an effect lasting about six weeks. 
BTX-A has been used more widely to treat the overactive bladder, detrusor 
hyperreflexia and sphincter dyssynergia. Side effects of BTX-A including, 
nausea, vomiting, dry mouth, dysphagia, weakness of respiratory muscles 
and paralysis have been described following its use for various dystonias and 
other indications. As regards patients treated locally for lower urinary tract 
dysfunction, in the literature there is a single case report of generalised
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muscle weakness 198. Reports of 200 to 300 IU of BTX-A injected for detrusor 
hyperreflexia, in spinal cord injured patients describe a protracted effect 
lasting at least 24 weeks66.
A longer duration of action confers benefit. If the incidence of side effects 
proves similar, BTX-B because of its more limited action duration, might find a 
role as a means of testing tolerance to BTX treatment. Otherwise, it will 
presumably be limited to use in patients who have experienced tachyphylaxis 
with BTX-A. It is well-recognised that BTX is immunoreactive and stimulates a 
polyclonal-antibody response to its peptide structure.
Many of the antibodies do not influence efficacy but with time there may be 
degradation of effect, depending on the antibody binding site, so that the drug 
loses its influence, as has occurred with cervical dystonias and recently with 
detrusor hyperreflexia109’213'215. it has been found that there is very little 
cross-reactivity of antibodies between the different BTX molecules so that 
BTX-B should prove useful following attenuation of the primary response to 
BTX-A.
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7.3 FUTURE STUDIES
Many questions are raised by these studies. Future studies should include 
looking more closely into subgroups (neuropaths and non-neuropaths), which 
the present study was not able to.
It would be useful to study a larger group of patients with refractory detrusor 
overactivity, followed over a longer period of time with repeated injections.
A higher dose of Botulinum toxin B could be tried and a formal dose-titiration 
study would be useful in guiding therapeutic decisions.
The study showed the potential affinity of the toxin for autonomic nerves and I 
think this should be investigated further by means of properly powered trials. 
Peripheral autonomic effects could present a very significant hazard. In 
Guillaune Barre syndrome, the great fear and the cause of mortality is 
autonomic failure.
It would also be useful to look into developing specific strains of botulinum 
toxin (by means of genetic engineering) which would increase the longevity of 
its effects, decrease or minimise the side effects and hence cut down the 
need for repeated injections.
It would be helpful to generate a strain which encourages minimal antibody 
production.
In recent years there has been increasing evidence that BTX-A might also 
have analgesic properties216. Initially, this was thought to be due to relief of 
muscle spasm. However, botulinum has been shown to reduce peripheral 
sensitization by inhibiting the release of several neuronal signaling markers,
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including glutamate and substance P, and reducing c-fos gene expression. It 
may affect the sensory feedback loop to the central nervous system by 
decreased input from the muscle tissue, possibly by inhibiting acetylcholine 
release from gamma motor neurons innervating intrafusal fibers of the muscle 
spindle217 BTX-A has been used effectively for years in different conditions 
with muscular hypercontractions. Intradetrusor BTX administration blocks the 
acetic acid-induced calcitonin gene-related peptide (CGRP) release from 
afferent nerve terminals in the bladder mucosal layer in rats. In an animal 
model of bladder permeability barrier disruption, intradetrusor BTX-A 
minimized bladder irritability and restored afferent neural responses to 
baseline levels218. These results support clinical trials of BTX-A for the 
treatment of PBS/IC and other types of visceral pain 219.
A multi-institutional case series using Botox or Dysport intradetrusor injections 
in 13 patients with refractory PBS/IC reported improvement in 9 patients. 
Improvements in symptoms lasted a mean of 3.72 months (range, 1 to 8 
months). No systemic complications were observed, although 2 patients had a 
diminished flow with some need to strain to void 22°. Rackley and colleagues 
at the Cleveland Clinic reported no change in objective or subjective outcome 
measures in a series of 10 PBS/IC patients in whom the trigone was spared in 
the injection technique221. At this time, Botox can be recommended for 
PBS/IC use only in the context of carefully controlled clinical trials.
The clinical method adopted for this study deserves some comment. For 
many years now, the standard approach for testing the efficacy of treatments 
for the overactive bladder has been the parallel group study. It would seem
that this is based on the assumption that a carry-over effect following the first 
limb suing active treatment would result in a failure of discriminating power. It 
is interesting to note that the available literature does not describe the length 
of drug effect, nor a time series describing the change in symptoms following 
the cessation of an antimuscarinic agent. Some believe that the measurement 
frame would be compromised by the more protracted influence of a bladder 
training effect. A recent J Urol publication challenges the effect of bladder 
retraining on urinary incontinence.222
In this study we worked on the assumption, based on previous work, that the 
carry-over effect would be small so as not to cloud a therapeutic response. 
This proved to be the case. If there were a training effect, both pathways 
would be similarly affected. If there were a drug carry over effect it would be 
likely to be markedly attenuated.
In crossover studies all patients serve as own controls and error variance is 
reduced thus reducing the sample size needed; All patients receive treatment 
(at least some of the time). Statistical tests assuming randomisation can be 
used validly. Blinding can be maintained. Thus the design experiments with 
the same power to influence practice but with a fraction of the cost and a 
sample size that makes a single-centre operation feasible.
The disadvantages are that all subjects receive placebo or alternative 
treatment at some point. The washout period could be lengthy or unknown,
although this study illustrates how this can be overestimated. It cannot be 
used for treatments with permanent effects.
Since clinical trials of treatments for the overactive bladder were first 
attempted, the sample sizes used have been increasing. Two recent 
controlled trials randomised 911 and 1081 patients, respectively in order to 
detect a between groups differences of 1 micturition episode per 24 
hours223 224. However, in 1999 a similar study randomised 316 patients in 
order to effect the same analysis 225. Inflation in recruitment is far from ideal 
since it proves time-consuming, expensive, demanding of logistical effort and 
inconvenient for the patients. It is not reasonable to randomise large numbers 
of patients to placebo if the hypothesis could be tested as well with a smaller 
sample.
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7.4 CONCLUSIONS
This study provides evidence of efficacy of Botulinum Toxin B in the treatment 
of the overactive bladder. The data suggest that this formulation and dose has 
a rapid onset of action (24 to 48 hours) but short duration, about six weeks.
However, it is not without any side effects. There was evidence of dry mouth, 
constipation, urinary retention and ‘flu-like’ syndrome which suggested the 
affinity of the toxin for autonomic nerves and its potential systemic absorption.
The experiment illustrates the utility of a cross-over design. This has not been 
favoured for studies of urinary incontinence because of speculative beliefs 
about the influence of carry-over effects confounding the treatment response.
Unlike an oral medication, with a short half-life, BTX-B showed measurable 
effects up to six weeks and there is evidence of a carry-over into the placebo 
arm.
Botulinum toxin B, because of its more limited action duration, might find a 
role as a means of testing tolerance to Botulinum toxin class, although this 
hypothesis would require testing. Otherwise, it will presumably be limited to 
use in patients who have experienced tachyphylaxis with Botulinum toxin A.
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PA TIENT IN FORMA TION SHEET
EFFECTS OF BOTULINUM TOXIN ON UNSTABLE BLADDERS
We are inviting you to take part in this research for the treatment of your 
unstable bladder. Before you decide, it is important that you understand why 
the research is being done and what it will involve and any risks that there 
may be in taking part. Please take time to read the following information 
carefully and discuss it with friends, relatives and your GP if you wish. Ask us 
if there is anything not clear or if you would like more information. Take time to 
decide whether or not you wish to take part.
What is the purpose of the research?
To find a possible cure for the unstable bladders so reducing the discomfort 
caused by urgency and incontinence and the repeated visits to the toilet
associated with it.
Why you?
You have been asked to participate because you have an unstable bladder 
and have tried other forms of treatment without any success. A total of twenty
patients will be invited to participate.
Are you obliged to take part?
|No.It is up to you to decide whether or not to take part. If you do decide to 
take part you will be given this information sheet to keep and be asked to sign 
a consent form. You are free to withdraw from the study at anytime and 
without giving any reason. This will not affect the standard of care you receive.
SPECIAL NOTE
THIS ITEM IS BOUND IN SUCH A 
MANNER AND WHILE EVERY 
EFFORT HAS BEEN MADE TO 
REPRODUCE THE CENTRES, FORCE 
WOULD RESULT IN DAMAGE
hat will happen to you if you take part?
You w ill then go home w ith  void ing 
diaries and questionnaire
You w ill be asked to sign the consent form
You report to the day ease unit w ith your 
vo id ing diaries and questionnaires
Botulinum  tox in / Placebo w ill then be injected at 10 
different sites in vour bladder
A  follow up telephone ca ll from us to ask about the well being 
/side effects at the end o f first week
A follow  up telephone ca ll from us to ask about the well being 
/side effects at the end o f first week
Under sedation (M ida /o lam ) and local anaesthesia Cystoscopy (Look inside the 
bladder) and three bladder biopsies w ill be performed
6 weeks later, you report again to day ease unit, w ith completed diary and 
questionnaire, for Cystoscopy (Cheek) and injection o f botulinum  toxin B 
/placebo. Void ing diaries and questionnaires w ill also be given to 
complete.
6 weeks later, you report outpatient c lin ic  w ith c , 'eted diary and 
questionnaire, for assessment o f  your symptoms and to cheek the progress.
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Effects on your daily life?
s There are no life style restrictions associated with the study.
✓ You can drive as normal the next day.
✓ There are no dietary restrictions.
s You can continue to take your regular medications.
^ You need to drink plenty of fluids over the next couple of days of the 
procedure to cleacr the small amount of blood you might notice in your 
urine.
What is the drug being tested?
Botulinum toxin is a neurotoxic drug safely used for the past 20 years to 
control various muscular disorders of a neurological origin. It is licensed for 
use in treating muscular spasms(in the neck and shoulders), excessive 
sweating of the armpits and treatment of spasticity, visual squints and some 
digestive tract problems. Botulinum toxin is not yet licensed for use in the 
bladder, however, in recent years physicians in both Europe and America 
have reported its successful use in treatment of bladder over activity, which is 
one of the commonest causes of urinary incontinence.
What are the possible benefits of taking part?
We hope that the treatment will help you. However, this can not be 
guaranteed. The information we get from this study may help us treat future 
patients with unstable bladders better.
What are the side effects of the treatment?
There are no known major side effects of the treatment as yet although a very 
few section of patients have experienced flu-like symptoms, dry mouth and 
drowsiness (less than 1%). No cases of paralysis of muscles outside the 
bladder have been reported.
However, after the procedure you may experience some blood (slight amount) 
in your waterworks for a couple of days which will clear up if you drink plenty 
of fluids for that time.
There is also slight risk of going in to retention of urine which may require self 
catheterisation for some time, however no cases of this side effect have been 
reported so far from similar studies.
What if new information becomes available?
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied. If this happens, your 
research doctor will tell you about it and discuss with you whether you want to
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continue in the study. If you decide to withdraw your research doctor will make 
arrangements for your care to continue. If you decide to continue in the study 
you will be asked to sign an updated consent form.
Also, on receiving new information your research doctor might consider it to 
be in your best interests to withdraw you from the study. He/She will explain 
the reasons and arrange for care to continue.
What happens when the research study stops?
This treatment will not be available after this research study stops. Many of 
other centres have been showing interest in this study and it might just be 
possible for the treatment to be available there.
What will happen to the results of my study?
The results of your study are likely to be published. In case you wish to get a 
copy of the published results, a copy may be requested for by your research 
doctor conducting the study.
What if something goes wrong?
We will take every care in the course of this trial. If through our negligence any 
harm results you will be compensated. However a claim may need to be 
pursued through legal action. The NHS Trusts are not permitted to carry 
indemnity for non-negligent (no fault) harm.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the study will 
be kept strictly confidential. Any information about you which leaves the 
hospital/surgery will have your name and addresses removed so that you 
cannot be recognised from it.
Who is organising and funding the study?
The study will be conducted at the Whittington hospital. The research is not 
being sponsored by any drug company, however the drug so required will be 
provided by the manufacturers of the same (ELAN PHARMA).
Who has reviewed the study?
This studied has been reviewed by the W hittington Hospital Research 
Ethics Committee.
2(X)
Contact for further information?
The following doctors will be involved in the study:
Mr. Ron M ille r : Consultant Urologist, Whittington hospital
Prof. James Malone-Lee: Consultant, Department of Medicine, Whittington
hospital
Dr. Maneesh G he i: Research registrar, Whittington hospital
You may contact them at any time through the hospital switchboard 
02072723070
You will be given a copy of this Information sheet and a signed consent 
form to keep
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CONSENT FORM
(version 2 dated 23rd June 2(X)3)
Title of Project:
Effects of Botulinum Toxin on Unstable Bladders
Name o f Researcher:
Prof. James Malone-Lee (Consultant, Dept, of Medicine)
Maneesh Ghei (Research Registrar)
Ron Miller (Consultant Urologist) &
Senthil Nathan (Consultant Urologist)
Please initial box
1. I confirm  that I have read and understood the in form ation sheet dated 23rd June
2(X)3 (V ers ion .. .2) or the above study and have had the opportunity to ask _____
questions.
2. I understand that my participation is voluntary and that 1 am free to w ithdraw at any 
time, w ithout giving any reason, w ithout my medical care or legal rights being 
atleeted.
3. 1 understand that sections o f any o f my medical notes may be looked at by 
responsible individuals from W hitting ton  Hospital or from  regulatory authorities 
where it is relevant to my taking part in research. I give perm ission for these 
individuals to have access to my records.
5. 1 also understand that the biopsies obtained from  my bladder w ill be used for 
histopatholoeieal examination and other analysis and 1 give nn  perm ission for the 
same. These tissues ma\ be treated as donation from  me and 1 have been told that 
there w ill be no financial remunerations for supply ine the tissue to other organisations 
o r individuals.
4. I agree to take part in the above study .
Name o f  Patient Date Signature
Researcher Date Si iz nature
